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Polyamines are ubiquitious 
molecules essential for cell 
proliferation. However, the 
role of polyamine metabolism 
in the immune response, 
hematopoiesis, and bone 
remodeling is largely unknown 
and was thus addressed in this 
study. The study showed that 
enhanced activity of spermidine/
spermine N1-acetyltransferase 
(SSAT), a catabolic regulator of 
polyamines, was associated with 
disturbed hematopoiesis and bone 
remodeling in mice and myeloid 
leukemias in humans.
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ABSTRACT 
 
Polyamines are ubiquitous molecules essential for cell proliferation. Induction of the 
catabolic enzyme of polyamines, spermidine/spermine N1-acetyltransferase (SSAT), is 
successfully used to limit cancer cell growth in cell culture. In animal models, however, 
SSAT overexpression has been shown to increase susceptibility to cancer. In the present 
study, the role of enhanced polyamine catabolism in homeostasis of hematopoietic and 
bone systems were investigated in mice overexpressing SSAT (SSAT mice) and its 
association to hematopoietic malignancies was studied with patient samples.  
The basal levels of serum and hepatic inflammatory markers of SSAT mice were 
comparable to those encountered in wild-type littermates. When exposed to endotoxin 
SSAT mice displayed a slightly enhanced anti-inflammatory response but the survival and 
symptoms of the SSAT mice were similar to those of wild-type mice. Further studies of cells 
and tissues of the immune system revealed that the hematopoietic phenotype of SSAT mice 
fulfilled the criteria of mouse myeloproliferative disease. 
The myeloproliferation of SSAT mice resulted from both the intrinsic SSAT 
overexpression of hematopoietic cells and microenvironmental factors. Characterization of 
the bone phenotype of SSAT mice showed altered structure of bones of SSAT mice to 
provide larger niche for hematopoietic cells. SSAT mice also showed cell-autonomously 
impaired osteoblastogenesis and increased number of premature osteoblasts. 
The association between SSAT activity and myeloproliferation was supported by 
findings from human leukemia patients. The SSAT activity in peripheral blood 
mononuclear cells of these patients was associated with the leukocyte number in myeloid 
leukemias but not in lymphoid leukemia. Further investigation of SSAT mice provided 
evidence that the association between SSAT and myeloproliferation might be mediated 
through epigenetic factors.   
Our results show that enhanced SSAT activity leads to aberrant bone formation and 
subsequent changes in bone marrow microenvironment. In conjunction with enhanced 
intrinsic SSAT activity of hematopoietic cells, this results in a myeloproliferative disease in 
SSAT mice. The role of SSAT activity in myelopoiesis is further supported by the 
association between SSAT activity and the white blood cell count in human myeloid 
leukemias. 
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TIIVISTELMÄ 
 
Polyamiinit ovat solujen kasvulle välttämättömiä molekyylejä. Niitä hajottavan entsyymin, 
spermidiini/spermiini-N1-asetyylitransferaasin (SSAT), indusointia on käytetty rajoittamaan 
viljeltyjen syöpäsolujen kasvua. Eläinmalleissa puolestaan SSAT-geenin yli-ilmentäminen 
on myös lisännyt alttiutta syövän synnylle. Tässä väitöskirjatutkimuksessa selvitettiin 
kohonneen polyamiinikatabolian roolia veren- ja luunmuodostuksessa SSAT-geeniä yli-
ilmentävillä hiirillä (SSAT-hiiret) ja sen yhteyttä verisyöpiin potilasnäytteillä. 
SSAT-hiirten seerumista ja maksasta mitattujen tulehdusmarkkereiden perustasot olivat 
verrattavia villityypin hiirten markkereiden tasoon. SSAT-hiirten vaste endotoksiinille oli 
kuitenkin lievästi tulehdusta hillitsevä. Tästä huolimatta eloonjääminen ja oireet olivat 
verrattavia villityypin hiiren vastaaviin. Immunologisten solujen ja kudosten 
lisätutkimukset osoittivat että SSAT-hiirten ilmiasu täytti hiirten myeloproliferatiivisen 
sairauden kriteerit.  
SSAT-hiirten myeloproliferatio syntyi yhdessä valkosolujen sisäisen SSAT:n yli-
ilmentämisen ja luuytimen mikroympäristön tekijöiden seurauksena. SSAT-hiirten luiden 
lähempi tarkastelu osoitti niiden muuttuneen rakenteen muodostavan suuremman tilan 
veren soluille. SSAT-hiirillä havaittiin lisäksi luuta muodostavien solujen (osteoblastien) 
erilaistumisen olevan ympäristöstä riippumattomasti häiriintynyt ja epäkypsien 
osteoblastien määrän kasvaneen.  
SSAT-aktiivisuuden ja myeloproliferaation välillä havaittua yhteyttä vahvisti ihmisen 
leukemianäytteiden tutkimus. Leukemiapotilaiden perifeerisen veren mononukleaaristen 
valkosolujen SSAT-aktiivisuus oli yhteydessä valkosolumäärään myeloista mutta ei 
lymfoista leukemiaa sairastavilla potilailla. Lisätutkimukset SSAT-hiirillä viittasivat 
epigeneettisten tekijöiden olevan yhteydessä SSAT-geenin ja myeloproliferaation välillä 
havaittuun suhteeseen.  
Saamamme tulokset osoittavat kohonneen SSAT-aktiivisuuden johtavan epänormaaliin 
luunmuodostukseen ja siitä johtuen poikkeavaan luuytimen mikroympäristöön. Yhdessä 
veren solujen kohonneen sisäisen SSAT-aktiivisuuden kanssa tämä johtaa 
myeloproliferatiivisen taudin kehittymiseen SSAT-hiirillä. SSAT-aktiivisuuden osuutta 
myelopoieesissa tukee lisäksi havainto SSAT-aktiivisuuden yhteydestä valkosolumäärään 
myeloista leukemiaa sairastavilla potilailla.  
 
 
Yleinen Suomalainen asiasanasto: epigenetiikka; hiiret; ihmiset; immuunijärjestelmä; leukemia; luuydin; 
luusto; polyamiinit; veri 
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1 Introduction 
Cancers in general result from disturbances of several normal cellular functions at the same 
time. Tissue homeostasis is disrupted also during the normal aging process due to 
alterations occurring at the molecular level and these changes can predispose to cancer 
development. In addition to cell-autonomous factors, the surrounding stroma may 
contribute to the malignancy of neoplasias. Thus, elucidation of the function of factors 
predisposing to cancer represents one way to prevent cancer development.  
All blood cells, including platelets, red blood cells and white blood cells, are derived 
from multi-potent hematopoietic stem cells.  Platelets, which originate from 
megakaryocytes, are involved in blood coagulation process whereas the function of red 
blood cells is to bind oxygen and deliver it to tissues. White blood cells, further subdivided 
into myeloid and lymphoid lineages, are responsible for the immune defense of body. In 
the hematopoietic system the disruption of tissue homeostasis with aging leads not only to 
an increased propensity to anemia but also to the attenuation of lymphoid lineage and 
further to dominance by myeloid lineages (Woolthuis et al. 2011). The domination of 
myeloid lineages is connected to the increased incidence of myeloid leukemias observed in 
the elderly. In addition to cell-intrinsic factors, recently much attention has been focused on 
the role of the micro-environment in the development of hematological malignancies 
(Askmyr et al. 2011; Carlesso and Cardoso 2010). 
Bone is a connective tissue consisting of cellular components as well as of an organic and 
inorganic matrix. Osteoblasts, osteoclasts and osteocytes are the cellular components of 
bone. Bone serves a variety of functions e.g. providing structural support and protection for 
internal organs as well as a suitable environment where hematopoiesis can take place. Bone 
is constantly being renewed by a process termed remodeling (Eriksen 2010; Kular et al. 
2012). This is carried out by bone-resorbing osteoclasts and bone-forming osteoblasts. The 
osteoclasts break down the old or damaged bone and osteoblasts re-fill the gap in the bone 
matrix. In healthy young bone the process of bone resorption and bone formation are 
tightly coupled to maintain homeostasis and overall bone mass. Thus, a defect in either of 
the events can evoke an imbalance in bone structure, leading to a disease state. 
Polyamines are small cationic molecules which have been conserved during the course 
of evolution. Due to their cationic nature, polyamines interact with negatively charged 
macromolecules (Igarashi and Kashiwagi 2010; Watanabe et al. 1991). Through these 
interactions, polyamines are involved in many cellular functions, with the best known 
being their function in cell proliferation. Polyamines have been linked also to neoplastic 
growth as biosynthesis of polyamines is enhanced in cancer cells as compared to healthy 
tissue (Wallace et al. 2003). In cell cultures, the induction of the activity of the catabolic 
enzyme of polyamines, spermidine/spermine N1-acetyltransferase (SSAT), has been 
successfully used to limit cancer cell growth (Kee et al. 2004b; Vujcic et al. 2000). In animal 
models, however, also opposite results are found; SSAT overexpression has been reported 
to enhance the animal’s susceptibility to skin and intestinal cancer (Coleman et al. 2002; 
2 
Tucker et al. 2005). Additionally, human breast cancer patients have been shown to exhibit 
increased SSAT activity in their tumor cells compared to healthy tissue (Wallace et al. 2000).  
This study aimed to reveal the role of disturbed polyamine metabolism in tissue 
homeostasis of the hematopoietic system. Thereby, polyamine levels and activity of their 
metabolic enzymes were measured from leukemia patient samples. Furthermore, the 
immunological and hematopoietic phenotypes of SSAT overexpressing mice were 
examined. These mice were shown to develop a myeloproliferative disease with the bone 
marrow microenvironment partly contributing to its development. Thus, in order to clarify 
how the microenvironmental factors could affect hematopoiesis the bone remodeling status 
of SSAT mice were also characterized. 
  
3 
2 Review of the literature  
2.1 POLYAMINE METABOLISM  
Polyamines are amino acid-derived aliphatic molecules found in all eukaryotes and nearly 
all prokaryotes (Cohen 1998). The three polyamines present in mammalian cells, putrescine, 
spermidine and spermine, contain two to four amino groups and at physiological pH they 
are fully protonated and possess cationic characteristics (Figure 1). Unlike the divalent 
inorganic cations, like Ca2+, the positive charge in polyamines is distributed along the 
carbon backbone. Thus, polyamines bind readily to negatively charged macromolecules 
such as DNA, RNA and proteins and therefore the proportion of free cellular polyamines is 
small (Igarashi and Kashiwagi 2010; Watanabe et al. 1991). Spermidine and spermine 
interact more strongly with macromolecules than putrescine. The ratio of spermidine and 
spermine is claimed to be important for cellular functions (Pegg and Michael 2010). The 
cellular content of spermine equals or exceeds that of spermidine only in animal tissues 
whereas not all prokaryotic species contain spermine at all. Putrescine is often considered 
as the precursor molecule and spermine as a reservoir molecule for spermidine. However, 
both of these molecules have been shown to possess their own individual functions.  
In view of their ability to form ionic bonds with other molecules and, additionally, to 
serve as precursors for other molecules, polyamines are involved in many cellular 
functions, such as transcription, translation and cell signaling. As a result of their important 
role in these functions, it is recognized that polyamines are essential for normal cell growth 
and development of organisms (Nishimura et al. 2002; Pendeville et al. 2001). The cellular 
polyamine content and the activity of their biosynthetic enzymes increase rapidly when 
proliferation is induced (Wallace 2009). The depletion of the cellular polyamine content 
triggers growth arrest by reducing synthesis of nucleic acids and proteins whereas high 
concentrations of polyamines may be toxic to cells (Davis et al. 1992; Persson 2009). For this 
reason, cellular concentrations of polyamines are very tightly regulated. In addition to their 
requirement in cell proliferation, the conservation of polyamines across evolution is also 
evidence emphasizing biological significance of these molecules (Wallace et al. 2003). 
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Figure 1 Mammalian polyamines, putrescine, spermidine and spermine. Polyamines are small 
aliphatic molecules with two to four cationic amino groups. Positively charged amino groups 
enable interaction with negatively charged macromolecules such as DNA and RNA.  
 
2.1.1 Biosynthesis of polyamines 
The major source of polyamines in mammals is via de novo biosynthesis, whereas dietary 
polyamines and polyamine production by gut microflora make a smaller contribution 
(Wallace 2009). The biosynthesis of polyamines uses two amino acids, methionine and 
arginine, as precursors (Cohen 1998). Methionine is converted to S-adenosylmethionine 
(AdoMet) and L-arginine to L-ornithine and both are then further decarboxylated by S-
adenosylmethionine decarboxylase (SAMDC) and ornithine decarboxylase (ODC), 
respectively. The decarboxylation of L-ornithine results in the formation of the diamine 
putrescine. Spermidine is synthesized from putrescine, and spermine further from 
spermidine, by transfer of aminopropyl group which is provided by decarboxylated S-
adenosylmethionine. The enzymes which catalyze the transfer are spermidine synthase and 
spermine synthase. The metabolic pathway of polyamines is presented in Figure 2. 
2.1.1.1 Ornithine decarboxylase 
Ornithine decarboxylase (ODC) is a pyridoxal phosphate -dependent enzyme which 
catalyzes the decarboxylation of L-ornithine to form the diamine putrescine. ODC is one of 
the two rate-limiting enzymes of polyamine biosynthesis. The knockout of the gene and 
subsequent loss of intracellular polyamine pools is lethal in mice (Pendeville et al. 2001). 
ODC functions as a homodimer with two active sites (Coleman et al. 1994). The association 
between the two ODC subunits is relatively weak and the dimers exist in rapid equilibrium 
with the inactive monomers. ODC has a very rapid turnover rate for a mammalian enzyme. 
The depletion of cellular polyamine pools stabilizes the enzyme whereas in excess of 
polyamines ODC is directed to degradation. The degradation is brought about by 26S 
proteasome but instead of ubiquitination ODC associates with protein termed antizyme 
(AZ) that directs it to proteosomal degradation. AZ is synthesized and its degradation is 
5 
inhibited in response to an increase in cellular polyamine content. It binds the ODC 
monomer preventing formation of dimer and, thus, it inhibits enzymatic activity. On the 
other hand, AZ activity is regulated by antizyme inhibitor (AZI) which binds AZ more 
tightly than ODC and thereby releases ODC from ODC-AZ complex (Murakami et al. 
1996). ODC protein levels are controlled also by high cellular polyamine content through 
translational regulation.  
2.1.1.2 S-adenosylmethionine decarboxylase 
The second rate-limiting enzyme of biosynthesis of polyamines is S-adenosylmethionine 
decarboxylase (SAMDC) (Nishimura et al. 2002). Inactivation of mouse SAMDC gene and 
the subsequent loss of intracellular polyamine pools is lethal at early stage of development. 
SAMDC is synthesized as proenzyme which after intramolecular cleavage reactions forms 
α and β subunits (Pegg 2009). In mammals, SAMDC functions as a tetramer of two pairs of 
α and β subunits and, additionally, it contains a covalently bound prosthetic group, 
pyruvate. SAMDC catalyzes the decarboxylation of AdoMet producing an aminopropyl 
donor for synthesis of higher polyamines (Pegg et al. 1998). Decarboxylated AdoMet 
(dcAdoMet) is required in polyamine biosynthesis whereas the non-decarboxylated form of 
AdoMet is needed as a methyl group donor in methyl transfer reactions. The 
decarboxylated form is not suitable for this purpose. For this reason, the steady-state level 
of dcAdoMet is kept very low and SAMDC activity is highly regulated by polyamines at 
the transcriptional, translational and protein levels. Putrescine enhances the proenzyme 
processing and catalytic activity of SAMDC whereas high concentrations of spermidine and 
spermine suppress transcription and translation and accelerate turn-over rate of SAMDC 
(Kameji and Pegg 1987; Pegg 2009). SAMDC is degraded by 26S proteasome after 
polyubiquitination.  
2.1.1.3 Spermidine and spermine synthases 
Spermidine and spermine synthases are aminopropyl transferases that function as 
homodimers and use dcAdoMet as a donor of aminopropyl group (Ikeguchi et al. 2006; 
Pegg and Michael 2010; Wu et al. 2007). Mammalian aminopropyltransferases are highly 
specific for their acceptor molecules, putrescine and spermidine, from which spermidine 
and spermine are formed, respectively. The by-product of the process, 5’-deoxy-5’-
methylthioadenosine (MTA), strongly inhibits both spermidine and spermine synthase 
(Ikeguchi et al. 2006; Wu et al. 2008). However, MTA is normally rapidly degraded to 
adenosine and methionine and, thus, does not have a great inhibitory effect in vivo. 
Spermidine and spermine synthases are expressed constitutively and, unlike ODC and 
SAMDC, not readily induced (Ikeguchi et al. 2006; Pegg and Michael 2010). Rather their 
enzymatic activity is limited by the availability of their common substrate, dcAdoMet. 
2.1.2 Polyamine catabolism 
Spermine is converted to spermidine and spermidine to putrescine by the concerted action 
of two enzymes, spermidine/spermine N1-acetyltransferase (SSAT) and acetylpolyamine 
oxidase (APAO) (Casero and Pegg 1993). SSAT adds acetyl groups to aminopropyl end(s) 
of spermidine and spermine. The acetylated forms are then either exported or oxidized by 
APAO which cleaves the molecules to generate N-acetylaminopropanal and the smaller 
polyamine. Additionally, spermine can be converted directly to spermidine by spermine 
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oxidase (SMO) (Vujcic et al. 2002). Due to its ability to directly convert spermine to 
spermidine, SMO can be considered as a way to recycle the higher polyamines (Wallace 
2009). The spermidine/spermine N1-acetyltransferase (SSAT) pathway, on the other hand, 
can be considered to be mainly utilized for depletion of the polyamines as 
acetylpolyamines produced by SSAT are readily excreted. For this reason, acetylpolyamines 
are only rarely found in normal cells, however, these molecules can be found in high 
concentrations in cancer cells (Kingsnorth and Wallace 1985). Furthermore, acetylation of 
polyamines reduces their charge and thus decreases their functional ability and potency to 
bind anionic molecules. 
High levels of SSAT have been shown to increase polyamine flux (Janne et al. 2006; Kee 
et al. 2004b). The activity of SSAT decreases polyamine levels and to compensate the 
polyamine depletion ODC and SAMDC are induced. The increased flux increases 
consumption of ATP and acetyl-CoA in addition to increased production of toxic 
compounds such as H2O2. 
2.1.2.1 Spermidine/spermine N1-acetyltransferase 
Spermidine/spermine N1-acetyltransferase is considered as a key catabolic enzyme of 
polyamines (Pegg 2008). SSAT is a part of the GCN5-related N-acetyltransferase (GNAT) 
family. It is primarily a cytosolic enzyme, although there is evidence of its localization in 
mitochondria and nucleus as well (Holst et al. 2008; Uimari et al. 2009). SSAT is active as a 
homodimer. Using acetyl-CoA as a donor for acetyl group SSAT is able to acetylate N1-
position of spermidine and either end of spermine as spermine is a symmetrical molecule 
(Matsui and Pegg 1981). In addition, other molecules with the aminopropyl structure are 
excellent substrates for SSAT, whereas for example, putrescine with its aminobutyl group 
does not (Della Ragione and Pegg 1983). 
SSAT is stringently regulated by polyamines and other factors at many levels, e.g. 
transcription, mRNA processing, translation and protein stability (Casero and Pegg 2009; 
Pegg 2008). Polyamine analogues, several molecules (growth factors, toxic compounds, 
drugs) and various pathophysiological stimuli affect SSAT either directly or indirectly 
through the regulation of polyamine levels. In the presence of high levels of polyamines, 
transcription and translation of SSAT are increased whereas degradation of the protein and 
incorrect splicing of the mRNA are reduced (Pegg 2008). Cellular SSAT activity is very low 
under resting conditions but it can be readily induced by several factors and the stability of 
the otherwise short-lived protein can be enhanced (Matsui and Pegg 1981; Persson and 
Pegg 1984). When polyamines and polyamine analogues bind the SSAT protein, its half-life 
is greatly prolonged since this prevents the ubiquitination and subsequent degradation by 
the 26S proteasome (Coleman and Pegg 1997). Many polyamine analogs have strong effects 
on the regulation of SSAT and as they are not substrates for SSAT, their content is not 
reduced in response to its induction (Pegg 2008). 
2.1.2.2 Acetylpolyamine oxidase and spermine oxidase 
APAO is a peroxisomal FAD-dependent enzyme in the polyamine catabolic pathway 
catalyzing the turn-over of N1-acetylated polyamines back to spermidine or putrescine 
(Casero and Pegg 2009). Spermine can be converted back to spermidine also directly, 
without the acetylation step, through the action of SMO (Vujcic et al. 2002). Both reactions, 
oxidation by APAO or SMO, produce highly toxic by-products, hydrogen peroxide (H2O2) 
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and 3-acetoamidopropanal or 3-aminopropanal, respectively. APAO is located in 
peroxisomes and this means that any oxidizing compounds produced by APAO activity 
may be immediately detoxified by peroxisomal catalase. SMO, however, is located in the 
cytosol and nucleus. Thus, the reactive oxygen species (ROS) produced by its activity can 
be potentially more harmful to the cell (Murray-Stewart et al. 2008). APAO is constitutively 
expressed and its activity is limited by the availability of its substrates, the acetylated forms 
of polyamines, which are produced by action of SSAT (Holtta 1977; Vujcic et al. 2003). 
APAO has very poor ability to oxidize non-acetylated polyamines. SMO, on the other hand, 
is highly inducible and all of the analogues inducing SSAT also induce SMO expression 
(Casero and Pegg 2009). APAO activity has been shown to be low in breast cancer patients 
in comparison to healthy controls, thus partly contributing to the accumulation of cellular 
acetylated polyamines (Kingsnorth and Wallace 1985; Wallace et al. 2000). 
2.1.3 Polyamine transport 
In addition to biosynthesis and catabolism, polyamine uptake and export are important 
pathways in the regulation of intracellular polyamine content. If polyamine synthesis is 
prevented, then the transport system becomes critical for normal cellular growth. The 
polyamine transporters have been well documented in prokaryotes but the transport 
mechanisms in mammalian cells are not well characterized and no mammalian transporter 
genes have been cloned yet. Food contains large quantities of polyamines which are 
absorbed from the intestine and can be transported for use by cells throughout the body 
(Bardocz 1993). Additionally intestinal bacteria produce and excrete polyamines which can 
be taken up and utilized (Wallace et al. 2003). Due to the positive charge of polyamines, 
they require a transport system to permit exogenous uptake. Thus, cells take up polyamines 
from the environment through an active, energy-requiring, transport system (Seiler et al. 
1996). Two transport systems for uptake of polyamines have been recognized: a sodium-
dependent form that has a preference for putrescine (although it can transport also 
spermidine and spermine) and a sodium-independent form that is capable of transporting 
spermidine and spermine. Additionally, there has been postulated to be an endocytosis-
mediated mechanism for polyamine transport (Soulet et al. 2002).  
The uptake and export of polyamines seem to be mediated by different transporters 
since polyamine uptake-deficient mutant cells are able to excrete polyamines (Hyvonen et 
al. 1994). However, both systems are regulated by the same factor, AZ, which also functions 
as an ODC inhibitor (Sakata et al. 2000). The main polyamines to be exported are putrescine 
and acetylated polyamines (Seiler et al. 1996). Acetylated polyamines do not function as 
substrates for the polyamine uptake system and thus once exported, they are not 
reaccumulated into cells (Byers and Pegg 1989). Exported acetylpolyamines are transported 
to the kidneys and excreted in urine. In many cancers, it is known that there are elevated 
urinary acetylpolyamine levels (Seiler et al. 1981).  
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Figure 2 Mammalian polyamine metabolism. Polyamine synthesis uses amino acids as 
precursors. The polyamine metabolism can be considered as a cycle (red arrows). The higher 
polyamines are produced from the smaller forms (spermidine from putrescine and spermine 
from spermidine) by the action of biosynthetic enzymes, ODC, SAMDC, SPDSy, SPMSy, and can 
again be converted back to the smaller forms by catabolic enzymes SMO, SSAT, APAO. The 
polyamine cycle consumes metabolites such as Ac-Co and ATP and produces toxic compounds 
(ROS and reactive aldehydes). Ac-coA, acetyl-coenzyme A; APAO, acetylpolyamineoxidase; 
ARG, arginine; ATP, adenosine triphosphate; AZ, antizyme; dcAdoMet, decarboxylated S-
adenosylmethionine; MAT, methionine adenosyltransferase; MTA, methylthioadenosine; ODC, 
ornithine decarboxylase; ROS, reactive oxygen species; S-AdoMet, S-adenosylmethionine; 
SAMDC, S-adenosylmethionine decarboxylase; SMO, spermine oxidase; SPDSy, spermidine 
synthase; SPMSy, spermine synthase; SSAT, spermidine/spermine N1-acetyltransferase 
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2.1.4 Cellular functions of polyamines and SSAT 
Polyamines can stabilize DNA and protect it from damage that is caused by for example 
oxidation and radiation (Ha et al. 1998b; Newton et al. 1996; TABOR 1962). Additionally, 
among the polyamines, spermine has been reputed to exert protective roles also during 
inflammation as it inhibits post-transcriptionally pro-inflammatory cytokine production in 
human mononuclear cells (Ha et al. 1998a; Zhang et al. 1997b). Moreover, spermine has 
been shown to reduce carrageenan-induced edema and partially protect from cecal ligation 
and puncture -induced sepsis in mice (Zhang et al. 1997b; Zhu et al. 2009). Polyamines 
modify gene activation and gene silencing by modulating the transition of DNA from the B- 
to the Z-conformation, inducing chromosome condensation by neutralizing the charges on 
histone and chromatin phosphate and by regulating activity of the histone 
acetyltransferases (Fredericq et al. 1991; Hougaard et al. 1987; Thomas and Messner 1986). 
Polyamines are known to be able to influence protein synthesis at various stages by 
changing the structure of mRNA, tRNA and rRNA [reviewed in (Igarashi and Kashiwagi 
2010)]. Furthermore, polyamines can change protein conformation by undergoing 
interactions with acidic protein structures thereby disturbing their functions. Polyamines 
regulate also membrane potential of cells by interacting with glutamate receptors and ion 
channels (Donevan and Rogawski 1995; Williams 1997). 
The best recognized function of polyamines is their role in cell proliferation. Similar to 
the content of known cell cycle regulators, cyclins and cyclin-dependent kinases, also 
polyamine concentration and activities of polyamine metabolic enzymes fluctuate during 
the cell cycle (Oredsson 2003). The activity of ODC, and subsequently the polyamine levels, 
peak at G1 and G2 phases whereas AZ and SSAT expressions are up-regulated during the 
G2/M phase. The dramatic changes in putrescine concentration during cell cycle suggest 
that this divalent polyamine directly drives cells through G1 restriction point to S phase 
(Bettuzzi et al. 1999). Additionally, a specific role of spermidine in eukaryotic cell 
proliferation is its posttranscriptional protein modification function in the formation of 
eukaryotic elongation factor 5A, eIF5A. Spermidine serves as the sole precursor of 
hypusine, a rare amino acid, which is required in the maturation of eIF5A (Park et al. 1981). 
The maturation of eIF5A is prevented not only by depleted spermidine pools but also by 
accumulated putrescine (Tome et al. 1997). Polyamines have a bivalent role in the 
regulation of cellular functions as, in addition to cell proliferation, they can regulate also 
apoptosis. The studies covering their role in inducing apoptosis are, however, 
contradictory. The depletion of polyamines has been shown to both induce and prevent 
apoptosis (Schipper et al. 2000). One can conclude from these studies that it is essential for 
cell survival to maintain cellular polyamine content within a narrow range. 
In addition to its central role in polyamine catabolism, the SSAT enzyme also possess 
other functions. SSAT is known to autoacetylate its own lysine residue (Bewley et al. 2006). 
Furthermore, SSAT can acetylate the deoxyhypusine/hypusine residue of eIF5A and, 
thereby, regulate its activity (Lee et al. 2011). It is possible that also other molecules function 
as substrates for SSAT. A recent study revealed SSAT to have an additional role in 
repression of expression of other proteins, however, the repression was restricted to 
exogenous proteins and only transiently transfected SSAT was able to exert any effects (Lee 
et al. 2010). The mechanism, however, is not yet known but the effect of SSAT action does 
not seem to depend on acetylpolyamines or on the depletion of polyamines. In addition, 
SSAT activity and the concomitant depletion of local polyamines is believed to induce 
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inward rectifier potassium channel Kir4.2 (Chen et al. 2004; deHart et al. 2008). 
Furthermore, SSAT binds α9β1 integrin and increased SSAT activity enhances cell 
migration through colocalization of α9β1 integrin and Kir4.2 (Chen et al. 2004). 
Furthermore, SSAT is linked to inflammatory responses through tumor-necrosis factor-α 
(TNF-α) and non-steroidal anti-inflammatory drugs (NSAIDs) which are able to induce 
SSAT activity (Babbar et al. 2007). Activation of SSAT will lead to polyamine depletion and 
hence to a reduction in cell growth and triggering of apoptosis. This may be beneficial in 
conditions of inflammatory stress. 
2.1.5 Polyamine catabolism in disease 
Studies of transgenic animals overexpressing or deficient for SSAT have pointed to a role 
for SSAT in many disease states where the effects of disturbed polyamine metabolism are 
mediated differently depending on the diseased tissue. A rapid depletion of spermidine 
and spermine increases the susceptibility to pancreatitis (Alhonen et al. 2000; Hyvonen et 
al. 2007). The accumulation of putrescine in hair follicles has evoked hair loss and skin 
problems in SSAT overexpressing mice (Pietila et al. 1997; Pietila et al. 2001). A similar 
polyamine profile and skin changes has been reported also in a patient with keratosis 
follicularis spinulosa decalvans (KSFD) (Gimelli et al. 2002). A lower consumption of acetyl-
CoA as a result of reduced SSAT enzyme activity has caused insulin resistance in SSAT 
knockout mice (Jell et al. 2007; Niiranen et al. 2006) whereas SSAT overexpressing mice 
exhibited an increased consumption of acetyl-CoA and ATP and, thus, they  represented 
the opposite phenotype (Pirinen et al. 2007). Increased production of ROS as a consequence 
of increased polyamine catabolism has been implicated in pathogenesis of 
ischemia/reperfusion injury in stroke and acute renal tubular necrosis (Tomitori et al. 2005; 
Zahedi et al. 2010).  
Since polyamines display such a strong positive correlation with cell growth, it is not 
surprising that the growth rate of cancer cells is also closely linked to the polyamine content 
of the cell. An increase in ODC activity and the subsequent increase in cellular polyamine 
pools have been considered to be an early event in several cancer cell types (Kingsnorth et 
al. 1984a; Kingsnorth et al. 1984b). It might be anticipated that inhibition of biosynthesis or 
enhancing the catabolism of polyamines would impair neoplastic growth. Decreased tumor 
incidence was indeed found in a tumorigenesis initiation study with mice overexpressing 
SSAT (Pietila et al. 2001). Furthermore, crossbreeding SSAT overexpressing mice with 
TRAMP mice, which develop prostate tumors reduced the incidence of tumors (Kee et al. 
2004a). However, SSAT overexpression has been linked also to increased susceptibility to 
tumor growth. The tumor cells of breast cancer patients have increased SSAT activity and 
decreased APAO activity in comparison to normal tissue (Wallace et al. 2000). The mouse 
model of K6/SSAT mice overexpressing SSAT only in skin exhibited increased tumor 
incidence in response to a two-stage tumorigenesis initiation protocol (Coleman et al. 2002). 
In a study where APCmin mice were crossed with SSAT overexpressing mice, the SSAT 
overexpression was associated with a susceptibility towards intestinal tumor growth 
(Tucker et al. 2005). However, in such a situation the effect of SSAT seemed to be indirect 
since prolonged exposure of intestine to increased levels of bile acid is known to predispose 
to carcinogenesis (Reddy et al. 1977) and the SSAT mice have been shown to suffer from an 
increased excretion of bile acids (Pirinen et al. 2010). 
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2.1.6 Polyamine metabolism in hematopoiesis  
In addition to other neoplasias , polyamine metabolism has also been linked to leukemias. 
The erythrocyte spermine content has prognostic value in childhood acute lymphoid 
leukemia (ALL) (Bergeron et al. 1997). In addition, the ODC activity in peripheral blood 
mononuclear cells from common myeloid leukemia (CML) patients has been shown to 
reflect the neoplastic proliferation activity of leukemic cells (Tripathi et al. 2002). 
Furthermore, the catabolic side of polyamine metabolism has been implicated in leukemias 
since SSAT is differentially expressed during different stages of CML pointing to an 
involvement of SSAT in disease transformation (Janssen et al. 2005). Additionally, SSAT 
expression is increased in the transition phase of acute megakaryoblastic leukemia (AMKL), 
a form of acute myeloid leukemia, common in individuals with Down syndrome (Lightfoot 
et al. 2004). Furthermore, SSAT is super-induced in response to treatment with 12-0-
tetradecanoylphorbol-13-acetate (TPA), a compound which triggers the differentiation of 
human myeloblastic leukemia cell line ML-1. Thus, SSAT was speculated to be an 
important regulator of myeloid differentiation (Wang et al. 1998).  
2.1.7 Polyamine metabolism in bone remodeling 
There are a few experiments describing the role of polyamines in bone formation (Tjabringa 
et al. 2008) and bone resorption (Yamamoto et al. 2012). Tjabringa et al (2008) showed that 
addition of spermine could enhance osteoblastogenesis in cultured mesenchymal stromal 
cells (MSC). Yamamoto et al. (2012) found spermidine or spermine treatment to prevent 
bone loss in ovariectomized mice. The effect of administered polyamines was mediated 
through disruption of osteoclast maturation. Polyamines did not have any substantial effect 
on osteoblasts in that study. Polyamine metabolism has been lined to bone homeostasis also 
in a human disorder called Snyder-Robinson syndrome (SRS) which is associated with 
mutations in the spermine synthase gene (Becerra-Solano et al. 2009; Cason et al. 2003; de 
Alencastro et al. 2008). SRS patients were reported to suffer from osteoporosis and the 
authors claimed that it resembled osteogenesis imperfecta, although, the diagnosis was not 
confirmed (Arena et al. 1996; Becerra-Solano et al. 2009; de Alencastro et al. 2008). SRS 
patients exhibit only a modest reduction in spermine but their spermidine content is greatly 
elevated (Cason et al. 2003). Thus, the spermine:spermidine ratio is reduced and the total 
polyamine content increased with the putrescine level being decreased. Additionally, mice 
lacking spermine synthase activity, termed gyro (Gy) mice, have been described to have a 
similar cellular spermine:spermidine ratio as SRS patients and also to suffer a defect in bone 
development in addition to other symptoms (Lyon et al. 1986; Mackintosh and Pegg 2000; 
Meyer et al. 1998). However, Gy mice have a deletion of a part of the X chromosome that 
inactivates not only the spermine synthase gene but also Phex, a gene that regulates 
phosphate metabolism. Therefore, caution is necessary in the use of Gy mice to study the 
role of spermine in bone formation (Wang et al. 2004). 
2.2 HEMATOPOIESIS 
Hematopoietic stem cells (HSC), like all other multi-potent stem cells in the body, are able 
to both self-renew and differentiate into more mature cells. Self-renewal is essential for 
maintaining the HSC compartment and hence is a prerequisite for lifelong hematopoiesis. 
HSC divisions can be either symmetrical or asymmetrical (Blank et al. 2008). During 
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symmetrical cell division, both daughter cells retain stem cell properties whereas in 
asymmetrical cell division one of the resulting daughter cells maintains stem cell properties 
but the other commits to a more differentiated outcome. As a result of symmetrical cell 
division, the stem cell pool is expanded. On the other hand, asymmetrical cell division 
maintains the HSC compartment. The more differentiated progeny progressively lose their 
self-renewal potential and become more restricted in their differentiation capacity. All 
circulating blood cells, including platelets, red blood cells and white blood cells, are 
descendants of multi-potent hematopoietic stem cells. Platelets (also called thrombocytes) 
are important participants in the blood coagulation process. They are derived by budding 
from large precursors called megakaryocytes. Red blood cells, or erythrocytes, bind oxygen 
and deliver it to tissues. During differentiation erythrocytes undergo denucleation in order 
to gain space for hemoglobin, the molecule able used for binding and transporting oxygen. 
White blood cells, also called leukocytes, are responsible for the immune defense in the 
body. They are further subdivided into myeloid and lymphoid lineages which both have 
several subpopulations with different specialized tasks in immune defense. The 
commitment of hematopoietic lineages is presented in Figure 3. 
 
Figure 3 Origin of hematopoietic and bone cells. Hematopoietic and bone cells both originate 
from the bone marrow. All the mature hematopoietic cells (right side of figure) develop from 
myeloid and lymphoid progenitors that differentiated from the hematopoietic stem cells. The 
bone destructing osteoclasts also have a hematopoietic origin whereas the bone forming 
osteoblasts derive from the mesenchymal stromal cells. CLP, common lymphoid progenitor; 
CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor; HSC, 
hematopoietic stem cell; LMPP, lymphoid-primed multipotent progenitor; MEP, megakaryocyte-
erythrocyte progenitor; MPP, multipotent progenitor; MSC, mesenchymal stromal cell; OB, 
osteoblast; OC, osteoclast 
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2.2.1 Hematopoietic stem cells 
The prevailing definition for murine hematopoietic stem cells is Lineage- Sca-1+ c-Kit+, 
designated as LSK cells (Ikuta and Weissman 1992; Li and Johnson 1995) (Figure 4.). These 
cells lack the lineage-associated surface markers but the expression of stem cell antigen 1 
(Sca-1) and c-Kit (also termed receptor for stem cell factor or CD117) is high. HSCs can be 
further classified into most primitive self-renewing stem cells, termed long-term 
hematopoietic stem cells (LT-HSC), and into more differentiated short-term hematopoietic 
stem cells (ST-HSC) and multipotent progenitors (MPP). LT-HSCs are able to reconstitute 
the bone marrow of a transplanted animal. The ST-HSCs and MPPs, however, are capable 
to only short-term reconstitution. The LT-HSCs reside in Thy1.1lo, CD34-, CD38+, Flt3- or 
Hoechstlo fraction of the LSK population (Adolfsson et al. 2001; Goodell et al. 1996; 
Morrison and Weissman 1994; Osawa et al. 1996; Randall et al. 1996). There seems to be no 
clear-cut phenotypic definition, however, to distinguish ST-HSCs and MPPs from each 
other (Iwasaki and Akashi 2007a). HSC compartment is heterogenous in respect of the 
lineage and self-renewal potential of the cells and HSCs comprise distinct lineage biased 
clonal subtypes (Beerman et al. 2010b). These HSCs with differential lineage potential can 
be purified based on the expression of CD150 (Slamf1) (Beerman et al. 2010a). The human 
HSCs are defined by the expression of surface markers CD34 and CD38, the most primitive 
HSCs (LT-HSC) being lineage- CD34+ CD38- rhodaminelow (McKenzie et al. 2007). 
2.2.2 Maintenance of self-renewal capacity of hematopoietic stem cells 
Self-renewal capacity, i.e. a daughter cell maintaining its stem cell properties, is sustained 
by both the intrinsic factors present in the stem cells and the extrinsic cues of the 
microenvironment surrounding the cells. Many transcription factors, such as Gfi-1, Pbx1, 
interferon regulatory factor-2, thioredoxin-interacting protein and Nurr-1 are known to be 
important regulators of HSC quiescence (Li 2011). For example, Gfi-1 knockout in mice 
leads to an increase in the numbers of cycling cells within the HSC pool and the function of 
HSCs in bone marrow transplantation experiments is decreased (Hock et al. 2004). The 
homeobox (Hox) transcription factors, such as Hoxb4 and Hoxa9, are widely studied 
transcription factors indispensable for hematopoiesis. They are expressed preferentially in 
HSC and immature progenitor cell populations and are down-regulated during the 
differentiation of hematopoietic cells (Argiropoulos and Humphries 2007). The Hox family 
transcription factors have overlapping functions and the loss of one gene may be 
compensated for by the other members of this family. Quiescent HSCs have also a higher 
expression of GATA-2, although its exact role in quiescence regulation in vivo is not clear 
(Li 2011; Venezia et al. 2004). Additionally, p53 is important in ensuring that HSCs remain 
quiescent and thus the increased expression of p53 is related to aging of hematopoietic cells 
(Dumble et al. 2007). Several cytokines, such as IL-3, IL-6, IL-11, Flt-3 ligand, 
thrombopoietin (TPO) and stem-cell factor (SCF, c-kit ligand), have been proposed as 
regulators of HSC self-renewal and used in the in vitro expansion of HSCs (Blank et al. 
2008). However, only studies with TPO and SCF have provided sufficient evidence to 
support their important role as positive regulators of stem cell pool. The receptors for TPO 
and SCF, c-mpl and c-kit respectively, are expressed on HSCs. Many signaling pathways 
have been reported to regulate HSC self-renewal or promote expansion of these cells in 
vitro, but nonetheless, their function in vivo has proved to be less pronounced. This 
indicates that there are overlapping pathways to secure the control of HSC self-renewal. 
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The maintenance of the self-renewal capacity of HSCs and the promotion of 
differentiation of committed cells are regulated also by epigenetic factors, such as DNA 
methylation, histone modifications and non-coding RNA (Cedar and Bergman 2011; Scholz 
and Marschalek 2012). DNA methyltransferases (DNMTs) catalyze the addition of a methyl 
group to the 5’ position of the cytosine ring of DNA, especially to CpG dinucleotide 
sequences. The N-terminal histone tails are subject to a vast array of covalent modifications, 
including acetylation, methylation, ubiquitination, sumolation and phosphorylation. The 
acetylation of histones H3 and H4 by histone acetyltransferases (HAT) promotes the 
activation of transcription which is opposed by histone deacetylases (HDACs) that remove 
acetyl groups, resulting in the formation of heterochromatin. Histone methylation by 
histone methyltransferases (HMTs) can be a signal for either eu- or heterochromatin (active 
or inactive chromatin). Methylation of H3K4 is known to signal for euchromatin whereas 
methylation of H3K9 and/or H3K27 promotes the association of repressive proteins, such as 
polycomb-group (PcG) proteins. The PcG proteins repress the genes that are involved in 
cell-cycle regulation and differentiation (Radulovic et al. 2013). Bmi1 is one of the best 
studied members of PcG family. It is specifically expressed in non-differentiated 
hematopoietic cells and is required for HSC self-renewal. Although, there is no evidence 
that Bmi1 overexpression could itself induce leukemia, it is believed to be an important 
collaborating factor in leukemic transformation. Furthermore, other participants in 
epigenetics have been shown to take part in leukemogenesis (Plass et al. 2008). Thus, 
therapeutic agents targeting the enzymes of DNA methylation (DNMT inhibitors such as 
decitabine (5-aza-2'-deoxycytidine)) and histone modifications (HDAC inhibitors such as 
trichostatin A) are being actively developed, with some already in clinical use.  
Since HSCs reside in an environment where the oxygen tension is very low, the 
maintenance of low intrinsic oxidant levels has been proposed to be an important way of 
keeping HSCs quiescent. The ROS level of HSCs is lower than the ROS level of committed 
progenitor cells (Tothova et al. 2007). Forkhead transcription factors, FoxOs, have been 
reported to protect HSCs from oxidative stress and triple knockout of FoxO1, FoxO3 and 
FoxO4 resulted in an accelerated cycling of HSCs in mice (Tothova et al. 2007). 
Additionally, mice deficient for ATM, a cell-cycle checkpoint regulator directly 
downstream of FoxO3A, were shown to display increased ROS levels in HSCs which led to 
a defect in maintenance of HSC quiescence (Ito et al. 2004).  
2.2.3 Lineage commitment of hematopoietic cells 
The expression of Sca-1 decreases in the more differentiated cell populations being, low in 
common lymphoid progenitors (CLP) and negative in common myeloid progenitors (CMP, 
Figure 4). The receptor for interleukin 7 (IL-7Rα) can be used to distinguish these two 
populations from each other. IL-7Rα, an essential cytokine for T and B cell development, is 
up-regulated in CLPs and absent in CMPs (Akashi et al. 2000; Bhatia et al. 1995; Kondo et 
al. 1997). The mature blood cells of lymphoid lineage consist of small, round cells: T, B and 
natural killer (NK) cells. Early lymphoid progenitors reside in bone marrow but the true 
maturation of T cell lineage takes place in the thymus. Myeloid progenitors can be further 
divided into three subsets on the basis of the expression of CD34 and FcγRII/III: 
CD34+FcγRII/IIIlo CMPs, CD34-FcγRII/IIIlo megakaryocyte-erythrocyte progenitors (MEPs) 
and CD34+FcγRII/IIIhi granulocyte-macrophage progenitors (GMPs). CMPs can produce all 
types of myeloid colonies whereas MEPs and GMPs, which differentiate from the CMPs, 
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can generate only granulocytes (i.e. neutrophils, basophils and eosinophils), mast and 
macrophage-dendritic cells or megakaryocytes and erythrocytes, respectively (Arinobu et 
al. 2005; Iwasaki et al. 2005a). Dendritic cells can be derived also from CLPs (Manz et al. 
2001). The monopotent megakaryocyte lineage-committed progenitors, giving rise to 
platelets, have been identified in the CD9+ MEP fraction whereas the surface markers of 
monopotent erythrocyte progenitors, giving rise to red blood cells, have not been 
characterized (Iwasaki and Akashi 2007b; Nakorn et al. 2003). 
Although the above definition for the distinct common lymphoid and myeloid 
progenitors derived from MPPs is widely used, there is some evidence that the 
differentiation routes of hematopoietic cells may be more complex [reviewed in (Iwasaki 
and Akashi 2007a)]. The postulated model implies that myeloid differentiation can occur 
not only through MPP-CMP pathway but also through lymphoid-primed multipotent 
progenitors (LMPP) (Adolfsson, Mansson et al. 2005, Lai, Kondo 2006). LMPPs, defined by 
the expression of Fms-like tyrosine kinase 3 (Flt3) and vascular cell adhesion protein 1 
(VCAM-1), are lymphoid-biased but possess a granulocyte-macrophage potential. The 
myeloid-potential is gradually down-regulated and eventually silenced during the course 
of lymphocyte differentiation. The commitment to the lymphoid lineage is finally 
established when the cell loses all of its abilities to produce cells with a myeloid lineage, i.e. 
at the CLP stage. Megakaryocyte-erythrocyte differentiation is traditionally thought to 
occur through the MPP-CMP pathway but there is also evidence that MEPs can be 
generated directly from HSC-MPP compartment (Adolfsson et al. 2005; Friedman 2007; 
Iwasaki et al. 2005b). LMPPs lack megakaryocyte-erythrocyte potential.  
Figure 4 Differentiation path of murine hematopoietic stem and progenitor cells. The 
hematopoietic stem cells and the myeloid and lymphoid progenitors can be identified and 
divided into subtypes based on the expression levels of the surface markers c-Kit, Sca-1, CD34, 
IL-7R and FcγRII/III. CLP, common lymphoid progenitor; CMP, common myeloid progenitor; 
GMP, granulocyte-macrophage progenitor; LT-HSC, long-term hematopoietic stem cell; MEP, 
megakaryocyte-erythrocyte progenitor; MPP, multipotent progenitor; ST-HSC, short-term 
hematopoietic stem cell  
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2.2.4 Regulation of myeloid and megakaryocyte-erythroid lineage commitment 
The lineage commitment is controlled by transcription factors that selectively activate or 
silence a set of genes. The order in which certain transcription factors become expressed 
and the expression level of transcription factor can decide the lineage outcome (Graf and 
Enver 2009). The expression level and timing of transcription factors depend on both 
intrinsic and extrinsic signals. Additionally, transcription factors may undergo cross-
antagonistic interaction with each other, inactivating transcription factors that direct the 
differentiation of other cell types (Dahl et al. 2003; Nerlov et al. 2000; Rekhtman et al. 2003; 
Zhang et al. 1999).  
PU.1 is one of the most important regulators of hematopoietic lineage commitment. It is 
highly expressed in myelomonocytic cells, B cells and at a lower level in their precursors, 
such as HSCs, CMPs and CLPs (Akashi et al. 2000). PU.1 regulates myelolymphoid 
differentiation and thereby its deficiency impairs the development of granulocytes, 
macrophages and lymphocytes but does not have any impact on the development of 
megakaryocytes or erythrocytes (McKercher et al. 1996; Scott et al. 1994). Conditional 
knock-out models have demonstrated PU.1 to be necessary for the maintenance of HSCs 
and indispensable in allowing MPPs to proceed to CMPs, GMPs and CLPs (Dakic et al. 
2005; Iwasaki et al. 2005b). Moreover, PU.1 expression favors myeloid over lymphoid 
development and monopoiesis over granulopoiesis (Dahl et al. 2003; DeKoter and Singh 
2000). C/EBPs are expressed predominantly in granulocytes, monocytes and eosinophils 
and C/EBPα also in HSCs, CMPs and GMPs but not in CLPs or MEPs (Friedman 2007; 
Traver et al. 2001). Mice deficient in C/EBPα lack neutrophils and eosinophils whereas this 
deficiency does not impact on lymphoid or megakaryocyte-erythrocyte development 
(Zhang et al. 1997a; Zhang et al. 2004). Moreover, C/EBPα is required to allow CMPs to 
proceed to GMPs as mice with a conditional deficiency of C/EBPα lack GMPs but the 
development of CMPs, MEPs and CLPs is normal. However, C/EBPα is not absolutely 
required for GMPs to differentiate into mature granulocyte-macrophages as demonstrated 
by disruption of C/EBPα at GMP stage (Zhang et al. 2004). Disruption of PU.1 at GMP 
stage, on the other hand, results in differentiation arrest (Iwasaki et al. 2005b). 
GATA factors are essential transcription factors for the development of megakaryocytes 
and erythrocytes (Iwasaki and Akashi 2007a). Enforced expression of GATA-1 in HSCs has 
been shown to lead to an increase in megakaryocyte-erythrocyte differentiation (Zhang et 
al. 2004). For further lineage specification, bipotent megakaryocyte-erythrocyte progenitors 
require the presence of additional signals. Erythroid Krüppel-like factor (Kfl-1) and friend 
leukemia integration 1 (Fli-1) have been identified as transcription factors directing 
erythrocyte and megakaryocyte commitment, respectively (Mancini et al. 2012). GATA-2 is 
crucial for the maintenance and proliferation of HSCs and multipotent progenitors (Vicente 
et al. 2012). It is normally down-regulated as hematopoiesis proceeds and it is likely 
repressed by GATA-1 (Crispino 2005).  
2.2.5 Aging of the hematopoietic system 
Similar to the homeostasis of other cellular systems, the cellular homeostasis of 
hematopoietic system becomes disrupted with age. The most striking feature of an aging 
hematopoietic system is the skewing towards a myeloid-biased output. The lymphoid 
output, on the contrary, is decreased and adaptive immunity concomitantly diminished. 
The incidence of myeloproliferative diseases increases with age whereas lymphoid 
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leukemias are more common in the young (Beerman et al. 2010b; Woolthuis et al. 2011). 
Elderly humans and mice have also a greater propensity to anemia. The age-related 
changes of hematopoietic system begins from HSCs whose population expands in 
advancing age and the repopulation capacity diminishes (Beerman et al. 2010a; Rossi et al. 
2005). During aging, the myeloid-biased (CD150high) HSC population expands whereas the 
proportion of HSCs with balanced lineage output (CD150low) diminishes. A comparison of 
old mice with their young counterparts has additionally revealed that the GMP population 
expands with age whereas the frequencies of CMPs and MEPs do not differ from those of 
young mice (Rossi et al. 2005). The gene expression profile of hematopoietic stem cells 
changes with age and epigenetic factors have been postulated as being important in this 
phenomenon (Woolthuis et al. 2011). 
2.2.6 Bone marrow microenvironment 
In recent years, it has become evident that the stromal cells surrounding solid tumors are in 
close contact with the tumor cells and they can promote the transformation of these cells 
into a malignant form. Hence, it is not surprising that also the microenvironment around 
hematopoietic cells has been claimed to play a role in development of hematological 
malignancies (Askmyr et al. 2011; Carlesso and Cardoso 2010). There is also evidence that 
leukemic cells are able to influence bone cells and thereby may further contribute to the 
severity of the hematopoietic disease (Edwards et al. 2008; Frisch et al. 2012).  
Early in life, hematopoiesis occurs in the yolk sac, the aorta-gonadal-mesonephros region 
and the liver. After bone forming cells (osteoblasts) have initiated the mineralization of the 
bone extracellular matrix, the hematopoietic stem cells move to the bone environment and 
in adults, hematopoiesis is localized in bone marrow. It is directed there by the calcium-
sensing receptor expressed on hematopoietic stem cells that enables cells to respond to 
extra-cellular ionic calcium concentrations (Adams et al. 2006). The bone marrow 
microenvironment is formed not only of the bone mineral matrix but also of cellular 
components, such as mesenchymal stromal cells, bone forming and destroying cells, 
perivascular cells and sympathetic neurons. Cells of the nervous system have been shown 
to support HSC quiescence by influencing the molecular and cellular components of the 
microenvironment (Katayama et al. 2006; Yamazaki et al. 2011). The vasculature of bone 
marrow is also recognized as being an important factor for hematopoietic homeostasis 
(Kopp et al. 2005). The most primitive HSCs are thought to line the endosteal walls of bones 
whereas the more differentiated progenitors reside in close proximity to the vasculature 
(Kopp et al. 2005; Zhang et al. 2003). HSCs from elderly individuals have been found to 
localize more distantly from endosteum due to their reduced adhesion to stromal cells 
(Kohler et al. 2009). Osteoblasts, lining the endosteal walls of bones, have been reported to 
be one of the key cellular components maintaining hematopoiesis (Calvi et al. 2003). The 
ablation of these cells leads to the concomitant loss of bone marrow cells (Visnjic et al. 
2004). Osteoblasts maintain HSCs by secreting thrombopoietin (TPO) and by expressing 
angiopoietin-1 (Ang-1), stem cell factor (SCF, c-kit ligand) and Jagged-1 on their surface 
(Blank et al. 2008; Li 2011). Additionally, the adhesion molecules present in osteoblasts such 
as N-cadherin, integrins and osteopontin anchor HSCs to the osteoblastic niche and 
regulate the cell-cycle quiescence of HSCs. Adipocytes, on contrary, have been considered 
to be negative regulators of hematopoiesis (Naveiras et al. 2009). In aging organisms, 
adipocytes seem to displace the hematopoietic cells in the bone marrow.  
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2.3 BONE STRUCTURE, FUNCTION AND DEVELOPMENT 
Bone serves a variety of functions providing, e.g. structural support and protection of 
internal organs. In addition, it maintains the body’s mineral homeostasis and serves as 
environment for hematopoiesis. Based on its structure, bone can be divided into cortical 
and trabecular compartments (Bilezikian et al. 2008). Cortical bone is called also compact 
bone due to its dense structure. It forms the hard outer layer of bones. Trabecular bone, on 
the other hand, is a porous network inside the area that cortical bone has bordered. As a 
result of its appearance, trabecular bone is often called spongy bone. In the long bones of 
the limbs, trabeculae can be found at the ends of the bones (epiphyses).  
Bone is a connective tissue consisting of cellular components, organic matrix and 
inorganic elements (Bilezikian et al. 2008). Osteoblasts, osteoclasts and osteocytes are the 
cellular components of bone, the latter accounting for 90 percent of bone cellularity. The 
most abundant protein in the organic bone matrix, representing over 90% of all the bone 
proteins, is type I collagen which is involved in the aligning of the mineral matrix. In order 
to assemble collagen molecules into fibrils, procollagen needs to be cleaved by specific 
proteinases. This process releases two propeptides, the amino-terminal PINP and carboxy-
terminal PICP whose serum concentrations reflect the rate of synthesis of type I collagen 
and therefore have been used as markers of bone formation (Pollmann et al. 2007; Rissanen 
et al. 2008). In addition, bone has also several non-collagenous proteins, such as osteopontin 
(OPN), bone sialoprotein (BSP) and osteocalcin (OC). In fact, circulating levels of OC can be 
used as a specific marker for osteoblastic activity and bone formation (Bilezikian et al. 
2008). Bone proteins are bound to hydroxyapatite crystals, the inorganic calcium phosphate 
constituent of the bone (accounting for approximately 60% of bone), and they serve 
important functions in the regulation of mineralization.  
During growth, bone formation occurs via two distinct mechanisms: intramembranous 
and endochondral ossification (Clarke 2008). The flat bones are formed by 
intramembranous ossification, a mechanism of direct bone formation. In endochondral 
ossification, on the other hand, the pre-existing cartilage template is replaced by the 
mineralized bone matrix. The cartilage growth plate has an integral role in the postnatal 
linear growth of the long bones, nevertheless, the long bones are formed by combination of 
these two mechanisms. The peak bone mass is achieved in adulthood, but thereafter bone is 
lost as a result of the normal aging process. This means that the bone formation exceeds 
bone loss in early life but the situation is reversed in the elderly.  
2.3.1 Bone remodeling 
After growth, bone appears to be a static organ. However, it is being constantly moulded 
and renewed by a process termed remodeling (Eriksen 2010; Kular et al. 2012). Bone 
remodeling allows repair of microdamage and replacement of old bone with new. It is 
generally thought that the purpose of bone remodeling is to maintain the mechanical 
properties of the skeleton as well as regulating mineral homeostasis. Remodeling is carried 
out by the bone-resorbing osteoclasts, breaking down the old or damaged bone, and the 
bone-forming osteoblasts, re-filling the gaps in the bone matrix. Signals from osteoclasts 
and the products of the resorbed matrix partly regulate osteoblastogenesis and bone 
formation (Martin and Sims 2005). However, human patients and mice with osteopetrosis 
due to impaired osteoclast function have normal or increased numbers of functional 
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osteoblasts, thus indicating that it is the number of osteoclasts, rather than their activity 
which is more crucial for osteoblastic bone formation (Karsenty 2000). Mesenchyme 
derived cells, such as osteoblasts and osteocytes, are important regulators of 
osteoclastogenesis and there are many regulatory factors influencing osteoclast formation. 
Some of these influence the cells indirectly by stimulating expression of 
osteoblastic/osteocytic receptor activator of nuclear factor kappa B ligand (RANKL). 
Osteoblasts regulate osteoclastogenesis additionally by secreting macrophage colony 
stimulating factor (M-CSF) (Udagawa et al. 1990). Previously, osteoblasts were thought to 
be the major regulatory cell type involved in osteoclastogenesis but in recent years, the 
important role of osteocytes has also been recognized (Xiong and O'Brien 2012). 
Additionally, osteocytes secrete sclerostin, a protein which inhibits bone formation (van 
Bezooijen et al. 2004).  
In healthy young bone, the process of resorption and formation are tightly coupled to 
maintain homeostasis and overall bone mass. Thus, a defect in either will cause an 
imbalance in bone structure leading to a disease state. An imbalance in cellular processes of 
bone remodeling is involved in serious bone diseases such as osteoporosis, osteosclerosis, 
osteopetrosis and Paget’s disease of bone (Kular et al. 2012). Osteosclerosis and 
osteopetrosis are diseases characterized by a marked increase in bone mass due to 
stimulated osteoblast activity and osteoclast dysfunction, respectively. Osteoporosis, the 
most common bone disease, on the other hand, is characterized by decreased bone mineral 
density and by deranged levels and forms of bone proteins. Osteoporosis is classified into 
primary and secondary diseases, with the primary form being further classified into 
postmenopausal (in women) and age-related (both women and men) osteoporosis. The 
pathophysiology of senile bone loss is characterized by bone formation exceeding bone 
resorption on the periosteal surface and bone resorption exceeding bone formation on the 
endosteal surface (Bilezikian et al. 2008; Clarke 2008). Consequently, bones increase in 
diameter and the marrow space expands in the elderly. Osteoporosis is preceded by a state 
called osteopenia in which there is a reduced bone mass, but not so extensive to fulfill the 
criteria of osteoporosis.  
2.3.2 Osteoblasts and bone formation  
Osteoblasts are cells of mesenchymal origin (Dennis et al. 1999; Pittenger et al. 1999) (Figure 
3). They are responsible for initial bone formation during development and later in bone 
remodeling. The maturation of osteoblasts from mesenchymal progenitors consists of three 
distinct phases: proliferation, extra-cellular matrix maturation and matrix mineralization. 
After mineralization, the majority of osteoblasts undergo apoptosis whereas the remainder 
of the population differentiates into osteocytes or quiescent bone lining cells. Osteocytes are 
cells that become trapped inside the bone-matrix. They are able to sense a mechanical load 
and subsequently send signals which cause bone to be either resorbed or formed. 
The runt-related transcription factor 2 (Runx2) is viewed as the master regulator in 
embryonic bone development as well as in postnatal differentiation and bone formation of 
osteoblasts (see (Ducy et al. 1999; Komori 2003; Stein et al. 2004) for a review). Mice lacking 
Runx2 do not produce any osteoblasts. Despite the essential role of Runx2 in osteoblast 
commitment, it is not needed for the maintenance of the major bone matrix genes in mature 
osteoblasts. Instead, it seems to function as a negative regulator of the terminal 
differentiation of osteoblasts (Liu et al. 2001; Marie 2008; Maruyama et al. 2007). Among 
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many other signaling pathways, Wnt/β-catenin pathway has been shown to be an 
important promoter of osteoblastogenesis through the stimulation of Runx2 (Gaur et al. 
2005). The bone cell phenotype is further reinforced by transcription factor Osterix (OSX) 
(Nakashima et al. 2002). OSX is believed to act downstream of Runx2 during osteoblast 
differentiation since it is not expressed in Runx2-deficient embryos but Runx2 is expressed 
in Osx-deficient mice. After proliferation, the expression of bone-matrix genes, such as type 
I collagen and fibronectin, increase in pre-osteoblasts and these cells turn into bone-matrix-
secreting osteoblasts. The expression of bone-matrix proteins osteocalcin, octeopontin and 
bone sialoprotein is increased in the mineralization phase in response to Runx2 promotion 
(Ganss et al. 1999; Neve et al. 2013; Sodek et al. 2000). These bone-matrix proteins have high 
affinity for the mineral constituent of bone, the hydroxyapatite crystal. The mineralization 
of the secreted matrix requires the presence of tissue non-specific alkaline phosphatase 
(TNAP/ALP), whose expression is increased along with the genes encoding bone-matrix 
proteins (Orimo 2010). ALP hydrolyzes pyrophosphate and provides the inorganic 
phosphate needed for hydroxyapatite crystallization. The hydroxyapatite crystals are 
formed within the matrix vesicles of osteoblasts (and chondrocytes) and deposited between 
collagen fibrils. Deactivating mutations in the TNAP gene are responsible for poorly 
mineralized cartilage and bones and also the accumulation of pyrophosphate. 
2.3.3 Osteoclasts and bone resorption 
Osteoclasts are multinucleated gigantic cells derived from the monocyte-macrophage 
lineage of hematopoietic cells (Walker 1975) (Figure 3). Despite sharing some cell-surface 
markers with macrophages, osteoclasts differ clearly from these cells, most distinctively by 
their ability to excavate bone (Chambers 2000). Upon reaching the bone matrix, 
mononuclear precursors fuse to form multinucleated osteoclasts which then become 
polarized. These polarized osteoclasts generate an isolated environment (sealing zone) 
between themselves and the bone and begin the degradation with the resorbing membrane 
(ruffled border) (Vaananen and Horton 1995). Osteoclasts secrete protons to lower the pH 
and, thus, are able to dissolve minerals from the bone-matrix (Bilezikian et al. 2008). 
Additionally, the matrix osteoclasts secrete enzymes, such as matrix metalloproteinases 
(MPPs) and cysteine proteinases, especially cathepsin K (CTSK), which degrade the organic 
components. When CTSK degrades the bone-matrix, collagen fragments, such as carboxy-
terminal cross-linking telopeptide (CTX), are released and thus the serum concentration of 
CTX reflects the resorbing activity of osteoclasts. The bone degradation products are 
transcytosed into vesicles via the resorbing osteoclasts from the ruffled border to the basal 
membrane. Tartrate-resistant acid phosphatase (TRAcP) is believed to function in the 
vesicles to undertake the final steps in the destruction of matrix components. The serum 
concentration of TRAcP5b has been shown to reflect the number of osteoclasts (Alatalo et 
al. 2004). After resorption, osteoclasts are subjected to apoptosis. The master transcriptional 
regulator of osteoclastogenesis is nuclear factor of activated T cells cytoplasmic 1 (NFATc1) 
(Zhao et al. 2010). NFATc1 regulates the expression of genes encoding adhesion molecules, 
proton pumps and bone-matrix degradation proteins, thus, modulating osteoclast 
migration, adhesion, differentiation and activation. NFATc1 is activated  by RANKL 
signaling which leads to the activation of several downstream molecules, for example NF-
κB, c-jun and c-fos.
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3 Aims of the study 
The main purpose of this study was to investigate the effects of activated polyamine 
catabolism on hematopoiesis and bone remodeling, and to evaluate the interplay between 
these two processes.  
 
The specific aims were: 
 
 To investigate the response of SSAT overexpressing mice to an immunological 
challenge 
 To characterize the hematopoietic phenotype of SSAT overexpressing mice and to 
assess the factors affecting the phenotype 
 To assess the role of SSAT activity in human lymphoid and myeloid leukemias 
 To characterize the bone phenotype of SSAT overexpressing mice and to elucidate 
the molecular mechanisms underlying the changes 
 
  
22 
 
  
23 
 
4 Materials and methods 
4.1 PATIENT SAMPLES 
Peripheral blood mononuclear cells (PBMCs) were obtained from 21 CML, 28 AML and 33 
ALL patients at time of diagnosis. Blood samples from AML and ALL patients were 
collected in the Department of Medicine at Kuopio University hospital in the years 
2001─2004. PBMCs were isolated (CPTTM tubes, BD Biosciences, Franklin Lakes, NJ) and 
stored at the Laboratory of Eastern Finland. Blood samples from CML patients were 
collected at the Helsinki University Central Hospital (Helsinki, Finland) during years 
2004─2011. PBMCs from CML patients were separated with Ficoll centrifugation (GE 
Healthcare Bio-Sciences, San Jose, CA, USA). Control PBMCs were obtained from healthy 
donors (n=5─12). The use of mononuclear cells taken at diagnosis in AML and ALL patients 
was accepted by the Ethical Committee of the North Savo Hospital District and by the 
National Supervisory Authority for Welfare and Health. The collection of samples from 
CML patients was approved by the Helsinki University Central Hospital Ethics. Written 
informed consents were obtained from all patients prior to sample collection. 
4.2 MICE 
Mice overexpressing the SSAT gene under its endogenous promoter (SSAT mice), their 
wild-type littermates (wt) and mice deficient in SSAT (SSATKO mice) were used in the 
experiments (Niiranen et al. 2006; Pietila et al. 1997). SSAT and wild-type mice were in 
C57BL/6JOlaHsd and SSATKO in C57BL/6J background. All animal experiments were 
approved by the National Animal Experiment Board of Finland.  
In the LPS experiments, mice were given a single intraperitoneal injection of 
lipopolysaccharide (LPS, E. coli strain 0111:B4, Sigma-Aldrich, 2 mg/kg as the non-lethal 
dose, 15 mg/kg or 30 mg/kg as the lethal dose) or saline (controls), n=3─10/group. Mice were 
monitored once every 1 to 2 hours and sacrificed at different time-points (and if in a 
moribund state). In bone marrow transplantation, the recipient mice (n=8─10/group) were 
lethally irradiated twice with a dose of 5.5 Gy (fractions 3 hours apart) one day before the 
transplantation. Donor bone marrow cells (5x106 cells/ 200 µl of PBS-2% FBS) were injected 
into the tail vein of the recipient mice under anesthesia. In cell proliferation studies, 1 mg of 
BrdU (BrdU Flow Kit, 557891, BD Biosciences, San Jose, CA) in PBS was administered 
intraperitoneally ten to eleven hours before sacrifice (n=6/group). In studies treating mice 
with drugs affecting epigenetic factors, the animals were subjected to daily intraperitoneal 
injections of decitabine (0.2 mg/kg, 5-Aza-2’-deoxycytidine, Sigma-Aldrich, St. Louis, MO, 
n=5─11) or trichostatin A (1 mg/kg, Selleck Chemicals, Houston, TX, n=7─9) for seven and 
ten days, respectively. Control animals received intraperitoneal PBS at a dose of 10 ml/kg. 
4.3 ISOLATION OF BONE MARROW CELLS FROM MICE 
Bone marrow cells were isolated from the bone marrow cavities of the hind legs by flushing 
with PBS-10% FBS. The cells were filtered through 40 µm strainers before being used in 
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flow cytometry (n=6─8 mice/group) or bone cell (osteoblasts and osteoclasts) differentiation 
experiments.  
4.4 EXPANSION OF FACS-SORTED LSK CELLS  
Sorted LSK cells pooled from six to eight mice were grown for 16 hours at 37ºC in 5% CO2 
in IMDM (Iscove’s modified Dulbeccos medium) supplemented with 1% BSA, 0.1 mM 2-
mercaptoethanol, 2 mM glutamine, human transferrin (200 µg/ml), bovine pancreatic 
insulin (10 µg/ml), low density lipoproteins (40 µg/ml), human Flt-3 ligand (100 ng/ml), 
human IL-11(100 ng/ml) and murine SCF (50 ng/ml). 
4.5 DIFFERENTIATION OF MESENCHYMAL STROMAL CELLS TO 
OSTEOBLASTS  
Osteoblast differentiation from mesenchymal stromal cells was conducted as described 
previously (Heino and Hentunen 2008). Shortly, bone marrow cells isolated from 4‒5 weeks old 
mice (n=4─6) were cultured in αMEM supplemented with 15% FBS, 10 mM HEPES, 50 
µg/ml gentamycin and 10 nM dexamethasone for one week at 37°C with 5 % CO2. Free-
floating cells were removed at day two of culture. Adherent cells, enriched for 
mesenchymal stromal cells, were detached by trypsin treatment and plated in six-well 
plates with 150 000 cells /well or in 24-well plates with 30 000 cells /well. Differentiation of 
osteoblasts was initiated by adding 10 mM Na-β-glycerophosphate (Sigma-Aldrich, St. 
Louis, MO) and 70 µg/ml ascorbate-2-phosphate (Sigma-Aldrich, St. Louis, MO). 
Dexamethasone was omitted on the third day of differentiation. The medium was changed 
on every third day and the cells were differentiated for up to 21 days. 
4.6 DIFFERENTIATION OF HEMATOPOIETIC CELLS TO OSTEOCLASTS  
Non-adherent bone marrow cells isolated from 4‒5 weeks old mice (n=4─6) were cultured 
in αMEM supplemented with 10% FBS, 50 µg/ml gentamycin and 5 ng/ml M-CSF (Merck 
Millipore, Billerica, MA) at 37°C with 5 % CO2. After 24 hours, the medium was changed to 
contain 30 ng/ml M-CSF. After an additional 48 hours, the cells were plated in equal 
numbers and osteoclast formation was induced by addition of 35 ng/ml RANKL (Merck 
Millipore, Billerica, MA). 
4.7 STATISTICAL ANALYSES  
Data are presented as mean ± SD when applicable. GraphPad Prism 5.03 software package 
(GraphPad Software Inc., LaJolla, CA) was used to perform the unpaired two-tailed 
Student’s t test and Pearson’s correlation analyses. P value < 0.05 was considered to be 
statistically significant. 
4.8 ANALYTICAL METHODS  
Peripheral blood samples were collected from hind leg saphenous vein or directly from the 
hearts of sacrificed mice into EDTA (ethylenediaminetetraacetic acid) -coated or serum 
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separator tubes (BD Diagnostic, Franklin Lakes, NJ). Table 1 lists the methods used to 
measure blood and serum analytes in the original publications I─IV. Table 2 summarizes 
the methods used to analyze tissue and cell samples as described in detail in the original 
publications (indicated in the table). 
 
Table 1. Analyses of blood and serum samples in original publications I─IV 
 
Analyte/ 
analysis 
Reference/kit/instrument Method Publ 
Blood count Sysmex k-4500 haematology analyser Flow cytometry II, III 
PINP Rat/mouse PINP EIA (IDS) EIA IV 
TRAcP5b Mouse TRAP Assay ELISA kit (IDS) ELISA IV 
OC Mouse osteocalcin RIA kit (Biomedical 
technologies Inc) 
RIA IV 
CTX RatLaps (CTX-I) EIA kit (IDS) EIA IV 
ALAT ALAT (GPT) FS* (IFFC mod.) kit (DiaSys) Spectrophotometry I 
Creatinine Merckotest Creatinine kit (Merck) Spectrophotometry I 
IL-1β Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I 
IL-6 Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I 
IL-10 Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I 
INF-γ Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I 
TNF-α Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I 
IgA (Kankaanpaa et al. 2009; Nissinen et al. 2012) Chemiluminescent 
immunoassay 
II 
IgM (Kankaanpaa et al. 2009; Nissinen et al. 2012) Chemiluminescent 
immunoassay 
II 
IgG (Kankaanpaa et al. 2009; Nissinen et al. 2012) Chemiluminescent 
immunoassay 
II 
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Table 2. Methods used to analyze samples in the original publications 
 
Method/analysis Tissue/cells Reference/kit Publ 
Cell smear PB, BM REASTAIN Quick-Diff kit 
(Reagena) 
II 
Histology L, K, S, Th, LN, BM  I─II 
von Kossa staining OB (Leskela et al. 2003) IV 
Bone length and diameter F, T  IV 
Ash weight T  IV 
Micro-computed 
tomography 
T (Bouxsein et al. 2010; Maatta 
et al. 2013) 
IV 
Biomechanical analysis F, T (Jamsa et al. 2001) IV 
ALP activity OB (Leskela et al. 2003) IV 
Polyamine concentration 
(HPLC) 
L, K, S, LN, BM, PBMC, OB, OC (Hyvonen et al. 1992) I─IV 
SSAT activity L, K, S, LN, BM, PBMC, OB, OC (Bernacki et al. 1995) I─IV 
ODC activity L, K, S, LN, BM, PBMC, OB, OC (Janne and Williams-Ashman 
1971) 
I─IV 
RNA analysis L TRIzol reagent (Invitrogen), 
High Capacity cDNA Reverse 
Transcription Kit (AB) 
I 
Quantitative real-time PCR LSK RNeasy Mini Kit (Qiagen), 
High Capacity cDNA Reverse 
Transcription Kit (AB) 
II 
Quantitative real-time PCR OB, OC TRIzol reagent (Invitrogen), 
High Capacity cDNA Reverse 
Transcription Kit (AB) 
IV 
Western blot PBMC  III 
Protein concentration L, K, S, LN, BM, LSK,  PBMC, OB, 
OC 
Protein assay kit (Bio-Rad) I─IV 
Magnetic separation BM Mouse hematopoietic 
progenitor cell enrichment kit 
(Stemcell Technologies) 
II 
Flow cytometry PB, S, BM, LSK  II 
PB, peripheral blood; BM, bone marrow; L, liver; K, kidney; S, spleen; Th, thymus; LN, lymph node; F, 
femur; T, tibia; OB, osteoblast; OC, osteoclast; PBMC, peripheral blood mononuclear cell; LSK, Lineage-
Sca-1+cKit+  hematopoietic stem cell  
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5 Results 
5.1 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM IN IMMUNE 
RESPONSE (I) 
To monitor whether the immune response of SSAT mice was altered compared to wild-type 
mice, the immune system of these mice was challenged with lipopolysaccharide (LPS). LPS 
is a structural constituent of the outer membrane of gram-negative bacteria. It activates 
immune and liver cells to produce pro- and anti-inflammatory mediators and ultimately 
causes endotoxemia leading to septic shock (Pinsky 2004). SSAT mice and wild-type mice 
had similar survival rates after administration of a lethal dose of LPS (I, Fig 1). However, 
SSAT mice begun to show early signs of inflammation (e.g. diarrhea and lethargy) slightly 
before their wild-type littermates. The histopathological changes observed in liver and 
kidneys after a non-lethal LPS challenge were similar in SSAT and wild-type mice (I, Fig 3 
and 4). The creatinine levels were also similar in both genotypes whereas serum ALAT 
activities were significantly higher in SSAT mice in comparison with the wild-type 
littermates (I, Fig 2). Thus, the liver of SSAT mice was affected to a greater extent than the 
liver of the wild-type mice to the LPS challenge. Serum concentrations of pro-inflammatory 
cytokines TNF-α and IL-6 were similar in SSAT and wild-type mice after a non-lethal LPS 
challenge whereas the increase in IL-1β and INFγ concentrations was greater in the wild-
type than in the SSAT mice (I, Fig 5). On the other hand, the concentration of the anti-
inflammatory cytokine IL-10 was higher in SSAT mice than in wild-type mice. The 
expression levels of hepatic acute-phase proteins C-reactive protein (CRP), haptoglobin and 
alpha-1-acid glycoprotein (AGP1) were increased in SSAT mice after a non-lethal LPS 
challenge whereas the level of expression of serum amyloid A (SAA1) was comparable to 
that of wild-type mice (I, Fig 6). In the basal state, levels of serum cytokines and hepatic 
acute-phase proteins showed no differences between genotypes. The lethal LPS challenge 
increased ODC activity in kidneys and liver in both genotypes (I, Tables 1 and 3). SSAT 
activity, on the other hand, was enhanced only in SSAT mice. Polyamine levels changed in 
accordance with the enzyme activities, i.e. putrescine was increased in both tissues in both 
genotypes, spermidine was decreased in liver and spermine in kidneys of SSAT mice. A 
non-lethal LPS challenge increased hepatic ODC activity and renal SSAT activity in SSAT 
mice (I, Table 2 and 4). The wild-type mice displayed no major changes in enzyme levels in 
either tissue. (Renal ODC activity was not analysed.) However, putrescine accumulated in 
both tissues in both genotypes. In addition, wild-type mice showed an increased level of 
spermidine in both tissues after the LPS challenge. N1-acetylspermidine accumulated 
mainly only in SSAT mice. 
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5.2 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM ON 
HEMATOPOISIS IN MICE (II) 
5.2.1 Polyamine cycle is enhanced in hematopoietic cells of SSAT mice  
Polyamine metabolism was disturbed in SSAT overexpressing mice in all of the 
hematopoietic tissues investigated, i.e. bone marrow, spleen, peripheral blood mononuclear 
cells, lymph nodes and macrophages (II, Fig 4, bone marrow). SSAT activity was 
significantly elevated as also was the activity of the biosynthetic enzyme ODC. Putrescine 
became highly accumulated and, uncharacteristically for mammalian cells, its concentration 
exceeded that of spermidine and spermine. In fact, the spermidine and spermine 
concentrations were decreased. Furthermore, the activity of SSAT increased N1-
acetylspermidine levels. The level of bone marrow SSAT activity was observed to be 
associated with the number of cells in bone marrow and with the weight of spleen.   
5.2.2 SSAT mice exhibit myeloproliferative phenotype 
The blood count of SSAT mice started to exhibit changes at sexual maturation and the 
changes became more drastic at an older age (II, Table 1). The number of mature 
neutrophils increased with age at the expense of lymphocytes which resulted in an elevated 
proportion of neutrophils. The number of platelets was significantly elevated after two 
months of age and in old SSAT mice there was evidence of anemia, due to a decreased 
number of erythrocytes. The splenic proportion of T cells (CD3+) was decreased and the 
proportion of B cells (B220+) was increased in SSAT mice (II, Table 2). Additionally, serum 
IgG levels were increased in SSAT mice compared to the wild-type. The ratio of CD4-
positive helper T cells to CD8-positive cytotoxic T cells (CD4+/CD8+) was significantly 
reduced and the proportion of regulatory T cells (CD4+CD25+FoxP3+) from all T cells was 
significantly higher in the peripheral blood and spleen of SSAT mice. Additionally, spleens 
were enlarged in SSAT mice (II, Fig 3). However, the histological sections of spleen, thymus 
and liver revealed no morphological differences between SSAT and wild-type mice and no 
infiltration of leukocytes or extramedullary hematopoiesis was observed in the liver of 
these mice. Bone marrow cellularity was significantly higher in SSAT mice and their bone 
marrow exhibited enhanced myelopoiesis and thrombocytopoiesis (II, Fig 2 and 3). The 
bone marrow architecture, however, was normal and no fibrosis was detected. The 
proportion of blast cells in the bone marrow remained unchanged. The numbers and 
proportion of common myeloid progenitors (CMP) and megakaryocyte-erythrocyte 
progenitors (MEP) from all bone marrow cells were significantly decreased whereas the 
numbers and proportion of granulocyte-macrophage progenitors (GMP) were elevated in 
SSAT mice (II, Fig 6). The number and proportion of LSK cells (including hematopoietic 
stem cells and multipotent progenitors) and more specifically, long-term hematopoietic 
stem cells (LT-HSC) also increased in SSAT mice. Proliferation of LSK cells was found to be 
increased in SSAT mice. However, there were no changes in the phases of cell cycle or in 
apoptosis of sorted LSK cells expanded in cell culture for 4 days. The expression of HSC 
self-renewal regulators Gfi1, Bmi1, GATA-2 and HoxB4 was comparable between wild-type 
and SSAT LSK cells as was the expression of a myeloid lineage commitment regulator 
C/EBPα. The expression of the megakaryocyte-erythrocyte commitment factor GATA-1 was 
increased whereas that of the myelo-lymphoid commitment regulator PU.1 declined in LSK 
cells.  
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5.2.3 The myeloproliferative phenotype of SSAT mice results from both the intrinsic 
factors of bone marrow cells and the bone marrow microenvironment 
Blood count analysis revealed that after short-term transplantation (up to ten weeks) wild-
type and SSAT recipients injected with SSAT bone marrow as well as the SSAT recipients 
receiving wild-type cells displayed an increased proportion of neutrophils compared with 
the wild-type animals transplanted with wild-type bone marrow (II, Fig 5). Neutrophilia 
remained present in all SSAT recipients after long-term reconstitution whereas the wild-
type environment attenuated blood count in long-term reconstitution in wild-type mice 
that received SSAT bone marrow. The most prominent phenotype was observed in those 
SSAT mice transplanted with SSAT bone marrow. The number of bone marrow cells was 
increased only in the SSAT recipients at the time of sacrifice (26 weeks). However, the size 
of the spleen was significantly increased in all SSAT recipients as well as in wild-type 
recipients transplanted with SSAT bone marrow in comparison to wild-type mice 
transplanted with wild-type bone marrow. The bone marrow cells of SSAT recipients and 
the wild-type mice transplanted with SSAT bone marrow had increased SSAT activity, an 
increased amount of putrescine as well as reduced levels of spermidine compared to wild-
type mice transplanted with wild-type bone marrow. 
5.3 SSAT ACTIVITY IN MYELOID AND LYMPHOID LEUKEMIAS AND 
EPIGENETICS IN HEMATOPOIETIC CELLS OF SSAT 
OVEREXPRESSING MICE (III) 
5.3.1 Polyamine metabolism of human leukemic blood cells is disturbed 
Levels of spermidine and spermine were significantly increased in peripheral blood 
mononuclear cells (PBMCs) of acute myeloid leukemia (AML), chronic myeloid leukemia 
(CML) and acute lymphoid leukemia (ALL) (III, Fig 1) patients compared with the healthy 
controls and the levels correlated positively with peripheral blood white blood cell (WBC) 
count and blast percentage. Additionally, the activity of SSAT was increased in all leukemia 
types. Interestingly, in myeloid leukemia patients (AML and CML), but not ALL patients, 
with the peripheral WBC count above the reference range SSAT activity was increased 
compared with the patients with normal or low peripheral blood WBC count. The SSAT 
activity correlated positively with the peripheral blood WBC count. After treatment, both 
the PBMC SSAT activity and WBC count of the follow-up samples of CML patients 
declined to the level of healthy controls. The activity of ODC and the level of putrescine 
were elevated only in ALL patients and the ODC activity correlated negatively with WBC 
count and blasts percentage.  
5.3.2 SSAT mice show epigenetic changes in hematopoietic cells and differential 
response to drugs affecting epigenetic factors  
The amount of methylation was significantly increased in tri-methylated lysine 36, 9 and 4 
residues and also in di-methylated lysine 79 residue of histone 3 in the bone marrow cells of 
SSAT mice compared to wild-type mice (III, Fig 4). The acetylation of histone 3 in lysine 9 
and lysine 14 residues and the level of histone deacetylase 1 (HDAC1) were also slightly 
increased in the bone marrow cells of SSAT mice compared to wild-type mice. Seven day 
treatment with decitabine, a DNA methyltransferase inhibitor used as an antileukemic drug 
in the therapy of human myeloid malignancies, evened up the changes in the peripheral 
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blood granulocytic and lymphoid cells between SSAT and wild-type littermates (III, Fig 2). 
In addition, the bone marrow cell number of SSAT mice was equal to that of the wild-type 
mice after treatment with decitabine. The SSAT activity of the bone marrow cells was not 
affected by the treatment. Ten day treatment with trichostatin A, a histone deacetylase 
inhibitor, did not affect WBCs of SSAT mice but significantly decreased the proportion and 
number of lymphocytes and increased the proportion of neutrophils in wild-type mice (III, 
Fig 3). The treatment also reduced the total WBC count in wild-type animals whereas in 
SSAT mice, the WBC count was unaltered. 
5.4 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM ON BONE 
REMODELING (IV) 
5.4.1 Polyamine metabolism of osteoblasts and osteoclasts is disturbed 
Polyamine metabolism of in vitro differentiated osteoblasts of SSAT overexpressing mice 
showed significantly increased SSAT activity, accumulation of putrescine and a decreased 
level of spermidine (IV, Fig 5). The spermine level was unaltered and there was no 
accumulation of the acetylated forms of polyamines. Interestingly, ODC activity was 
reduced in SSAT osteoblasts differentiated for 14 days but it increased as differentiation 
proceeded further. In SSATKO osteoblasts, ODC activity was decreased, the putrescine 
level was significantly reduced whereas spermidine and spermine levels remained 
unaltered when compared to wild-type osteoblasts. Polyamine metabolism of in vitro 
differentiated SSAT osteoclasts showed increased SSAT and ODC activities and 
accumulation of putrescine (unpublished data). Spermidine and spermine levels were 
unchanged and no acetylated forms of polyamines were detected. 
5.4.2 SSAT overexpression affects osteoblastogenesis but not osteoclastogenesis cell-
autonomously 
 Mesenchymal stromal cells of SSAT mice differentiated into osteoblasts in cell culture 
showed decreased ALP enzyme activity and a decreased number of mineralized calcium 
nodules as compared to osteoblasts of wild-type littermates indicating impairment in 
osteoblastogesis (IV, Fig 4). In contrast to SSAT osteoblasts, SSATKO osteoblasts showed 
increased osteoblastogenesis. The expression of the osteoblastogenic regulator OSX as well 
as of the osteoblastogenic marker genes ALP, OC, OPN and BSP were decreased in SSAT 
osteoblasts. On the other hand, expression of RUNX2, the master regulator of 
osteoblastogenesis, was not changed. However, as differentiation proceeded, the expression 
of RUNX2 and ALP increased, whereas that of the other genes was still significantly lower 
in SSAT osteoblasts as compared to the level of expression in wild-type cells. In vivo, the 
serum concentration of PINP, a marker of collagen deposition and thus bone formation, 
was slightly elevated in SSAT mice compared to wild-type mice (IV, Fig 3). The serum 
concentration of OC, a protein binding bone mineral matrix, on the other hand, was 
reduced in SSAT mice. The numbers of osteoclasts, differentiated in vitro from bone 
marrow cells, were comparable in wild-type and SSAT mice. The expression of the 
osteoclastogenic regulator NFATC1 was significantly increased in the osteoclasts of SSAT 
mice (IV, Fig 4). However, that did not reflect to the expression levels of the 
osteoclastogenic markers, TRACP and CTSK, as their levels were unaltered. In vivo, the 
concentration of the bone resorption marker reflecting the number of osteoclasts, TRACP5b, 
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was decreased in SSAT mice whereas the concentration of a marker of osteoclast activity, 
CTX, was comparable with that found in wild-type mice (IV, Fig 3). 
5.4.3 Induction of SSAT with α-methylspermidine disturbs wild-type 
osteoblastogenesis 
 Treatment of SSAT osteoblasts with α-methylspermidine did not have any effect on their 
defective differentiation potential (IV, Fig 6). The ALP activity of SSATKO osteoblasts was 
slightly, but statistically significantly, decreased after treatment with the analogue. 
Nevertheless, it remained markedly increased as compared to ALP activity of wild-type 
and SSAT osteoblasts. ALP activity and the number of mineralized nodules of wild-type 
osteoblasts, however, decreased to the level of those in SSAT osteoblasts after treatment 
with the analogue.  α-Methylspermidine induced SSAT activity in wild-type and SSAT cells 
but not in SSATKO cells lacking a functional SSAT gene. The activity of ODC was 
decreased similarly in all three genotypes compared to their untreated counterparts. The 
levels of natural polyamines decreased drastically in all three genotypes and they were 
replaced by the analogue. 
5.4.4 Bone phenotype of SSAT mice reveals striking changes 
 The skeleton of SSAT mice started to show changes at sexual maturation revealing 
kyphosis (hunched back). The diameter of femurs and tibiae were larger in SSAT mice (IV, 
Table 1). The length of the bones was increased only in males at the age of 5 months. The 
diameter and length of long bones of SSATKO mice, however, were unaltered. The bone 
mineral content of tibiae was increased in young SSAT mice but comparable between the 
three genotypes at older age. The bones of SSAT mice broke more easily than the bones of 
wild-type mice when subjected to compression whereas biomechanical studies showed that 
in response to a bending force, the bones of female SSAT mice had greater stiffness and 
strength (IV, Fig 2). The bones of male SSAT mice showed increased tibial but not femoral 
stiffness and strength. In contrast to SSAT mice, the bone strength of SSATKO mice in 
response to bending was slightly decreased in the tibiae in females and in the femur necks 
of the males. An investigation of tibiae of SSAT and SSATKO mice by computational micro-
tomography revealed drastic differences in their structure compared to wild-type mice (IV, 
Fig 1). The endosteal tissue volume (TV) of cortical bone was significantly larger in SSAT 
mice and the BV/TV ratio was significantly decreased. Additionally, the bone perimeter 
(B.Pm) showed a significant increase in SSAT mice whereas the cross-sectional thickness 
(Cs.Th) was reduced. The trabecular thickness (Tb.Th) was reduced and total volume of 
porosity (Po.V) was larger in SSAT mice. Additionally, in the 7 month old SSAT mice, the 
trabecular number (Tb. N) was increased. In SSATKO mice, both the cortical BV and TV 
were reduced resulting in a BV/TV ratio which was comparable to that in the wild-type 
mice. B.Pm and Cs.Th were unaltered in SSATKO mice. The Tb. N was reduced in SSATKO 
mice compared to wild-type. The bone mass density (BMD) was similar in SSAT and wild-
type mice whereas it was decreased in SSATKO mice when compared to wild-type mice.  
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6 Discussion 
SSAT is the key catabolic enzyme of polyamines. Activation of SSAT in mice concurrently 
enhances the whole polyamine cycle in many tissues which in addition to affecting 
polyamine levels, influences the availability of metabolites shared with other metabolic 
pathways and increases the production of toxic metabolites. The present work has 
characterized the role of enhanced polyamine catabolism in immune defense, 
hematopoiesis and bone remodeling.  
I Inflammatory challenge of SSAT mice 
Neutrophils are the first cells recruited to acute inflammatory sites. They bind surface 
structures of pathogens, such as lipopolysaccharide (LPS) of gram-negative bacteria. In 
consequence, neutrophils begin to produce cytokines to recruit other immune cells as well 
as enzymes and reactive oxygen species (ROS) to kill ingested bacteria. During the early 
stages of endotoxic shock neutrophils are known to be essential for suppression of 
bacteremia and the preservation of tissue function (Hoesel et al. 2005). However, in the later 
stages of endotoxic shock, neutrophils are themselves significant contributors to tissue 
damage and organ failure. These present results show that after exposing animals to a 
lipopolysaccharide (LPS) -induced endotoxic shock, the anti-inflammatory actions were 
enhanced and pro-inflammatory actions inhibited earlier in SSAT mice than in wild-type 
mice. Although, SSAT mice revealed an enhanced anti-inflammatory response at the 
molecular level during the early stage of LPS challenge, this had no effect on the mortality 
of these mice as it was comparable to their wild-type counterparts. The increased 
neutrophil numbers of SSAT mice (II) and the harmful effects of neutrophils at later stages 
of endotoxic shock could explain the end result of the inflammatory challenge. In further 
support of this proposal, SSAT mice had increased alanine aminotransferase (ALAT) values 
at 24 hours after the LPS-challenge, evidence of greater liver damage in the late stage of 
endotoxic shock.  
II-IV SSAT in myeloproliferation and association of hematopoiesis and bone phenotype 
in SSAT mice  
These present studies demonstrated that overexpression of SSAT in mice evoked a 
myeloproliferative phenotype that emerged at sexual maturity and progressed with age. 
The hematological phenotype of SSAT mice fulfilled the criteria of a myeloproliferative 
disease, according to the Bethesda proposal for classification of murine nonlymphoid 
hematopoietic neoplasms (Kogan et al. 2002). This was supported by the immunological 
studies which revealed that the basal levels of serum cytokines and acute phase protein 
expressions were comparable between SSAT and wild-type mice (I), thus suggesting that 
SSAT mice do not suffer from a systemic chronic inflammation. Furthermore, the 
hematological phenotype of SSAT mice was shown to originate partly from the intrinsic 
SSAT overexpression of hematopoietic cells as demonstrated by transplantation 
experiments. However, the bone marrow microenvironment was also shown to contribute 
to the development of myeloproliferation in SSAT mice with the most prominent 
hematopoietic phenotype being encountered when both the SSAT bone marrow cells and 
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the SSAT microenvironment were present. Nevertheless, the changes seen in bone structure 
and in bone forming cells of SSAT mice were in line with the increased hematopoiesis (IV).  
The myeloproliferative phenotype of SSAT mice implied that there had been changes in 
lineage commitment. This was indeed apparent already at the hematopoietic stem cell 
(HSC) level as the expression level of the lineage marker PU.1 was decreased and that of 
GATA-1 increased when compared to the expression levels in wild-type HSCs. PU.1 is an 
important regulator of the myelolymphoid lineage commitment and GATA-1 an essential 
transcription factor for the lineage commitment of megakaryocytes and erythrocytes at the 
HSC level (Iwasaki et al. 2005b; Iwasaki and Akashi 2007b). Mature granulocytic cells were 
extensively accumulated in the hematopoietic tissues of SSAT mice at the expense of 
lymphoid cells. This myeloid domination was apparent already at the progenitor level as 
the numbers of granulocyte-macrophage progenitors (GMPs) were elevated in SSAT mice. 
In addition to granulocytic accumulation, SSAT overexpression led to an increase in the 
number of platelets in SSAT mice as compared to wild-type mice whereas the numbers of 
MEPs, the common progenitor for megakaryocytes and red blood cells, were reduced as 
were those of mature erythrocytes. The findings from the mouse model were 
complemented by the studies of polyamine metabolism in human leukemia samples which 
revealed that the SSAT activity was associated with the white blood cell count in patients 
with myeloid leukemias (III). In contrast in lymphoid leukemia patients, the increased 
peripheral blood mononuclear cell SSAT activity did not correlate with the white blood cell 
count. Furthermore, the follow-up samples from treated chronic myeloid leukemia (CML) 
patients exhibited a normalized peripheral blood white blood cell count and additionally 
normalized peripheral blood mononuclear cell SSAT activity. An earlier study by Janssen et 
al (Janssen et al. 2005) has also pointed to a role for SSAT in myeloid leukemias as its 
expression was shown to differ during the different stages of CML (being highest in the 
chronic phase in comparison to the diagnosis or that in a blast crisis). Moreover, the 
expression of SSAT has been shown to be super-induced in response of 12-0-
tetradecanoylphorpol-13-acetate (TPA) induced differentiation of human myeloblastic 
leukemia cell line ML-1 (Wang et al. 1998). Interestingly, increased SSAT expression has 
also been related to megakaryocyte malignancy in a study which characterized genes in the 
transition phase of acute megakaryoblastic leukemia (AMKL), a form of acute myeloid 
leukemia in children with Down syndrome (Lightfoot et al. 2004). Taken together, the 
earlier studies and these present findings from mouse and human studies indicate that 
increased SSAT activity is linked to myeloid and megakaryocyte differentiation.  
Polyamines have been shown to play essential roles in the differentiation of many cell 
types (Facchini et al. 2012; Pietila et al. 2005; Vuohelainen et al. 2010). In SSAT mice, the 
accumulation of putrescine has been reported to disturb the differentiation of keratinocytes 
(Pietila et al. 2005). Also the hematopoietic cells of SSAT mice accumulated high levels of 
putrescine whereas the levels of spermidine and spermine were reduced. Despite the 
marked changes in the polyamine levels of hematopoietic cells, the polyamines do not seem 
to substantially affect hematopoietic cell differentiation or the hematopoietic phenotype of 
SSAT mice. Firstly, in a preliminary study, where wild-type and SSAT mice were treated 
for three months with 2% difluoromethylornithine (DFMO, an ODC inhibitor) to decrease 
the biosynthesis of polyamines, there were no changes detected in blood counts or bone 
marrow cell counts, i.e. SSAT mice still exhibited neutrophilia as compared to wild-type 
mice (unpublished data). However, DFMO treatment did reduce the levels of putrescine 
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and spermidine as well as the activity of SSAT in bone marrow cells of both genotypes. 
Nonetheless, the SSAT activity of the cells of SSAT mice remained higher than that of wild-
type mice. Secondly, the blood counts and spleen weights of SSATKO mice were evaluated 
but these mice did not exhibit any notable hematopoietic phenotype despite the alterations 
in their hematopoietic cell polyamine levels (decreased putrescine and increased 
spermidine concentrations, unpublished data). Thus, these results suggest that increased 
SSAT activity influences the myeloproliferation in SSAT mice which is in line with the 
present findings from studies of human leukemia samples described in earlier chapter.  
SSAT has been reported to possess also other functions in addition to regulation of 
cellular polyamine levels. For example, SSAT is able to bind integrin α9β1 and binding of 
SSAT with integrin α9β1 could potentially influence the differentiation of hematopoietic 
cells of SSAT mice as increased SSAT activity has been shown to enhance cell migration 
through binding of this integrin (Chen et al. 2004). Integrin α9β1 is widely expressed in 
many cell types, including neutrophils and hematopoietic stem cells (Grassinger et al. 2009; 
Hoye et al. 2012). Mice lacking integrin α9β1 have been shown to exhibit a dramatic 
impairment in neutrophil differentiation due to a defect in granulocyte colony-stimulating 
factor (G-CSF) mediated signaling (Chen et al. 2006). The numbers of granulocyte precursor 
cells and mature neutrophils are reduced in these mice. The results of Chen et al (2006), 
however, indicate that SSAT binding does not affect the interaction of integrin and G-CSF. 
Preliminary data from granulocytic cells of SSAT mice indicated that apoptosis of these 
cells seemed to be decreased as compared to wild-type granulocytes (unpublished data). 
Interestingly, in addition to playing a role in migration and differentiation, α9β1 is known 
to regulate cell survival of neutrophils by inhibiting apoptosis through vascular cell 
adhesion protein 1 (VCAM-1) binding (Ross et al. 2006). Thus, it is plausible that 
hematopoietic phenotype of SSAT mice is partly influenced by the interplay between 
integrin α9β1 and enhanced SSAT activity either through increased migration potential or 
decreased apoptosis.  
The enhanced catabolism in hematopoietic cells of SSAT mice enhanced the whole 
polyamine metabolic cycle as, in addition to increased SSAT activity, also the ODC activity 
was increased in the cells. The enhanced polyamine cycle could influence the availability of 
metabolites, such as acetyl-CoA, which are shared with other metabolic pathways and in 
this way it could affect hematopoietic cell differentiation (Jell et al. 2007; Kee et al. 2004a; 
Pegg 2008). The consumption of acetyl-coA by SSAT could potentially interfere with the 
acetylation processes conducted by histone acetyltransferases. However, it was found that 
the increased activity of SSAT did not decrease the acetylation status of H3 lysine 9/14 in 
bone marrow cells of SSAT overexpressing mice but rather increased it slightly (III). The 
protein level of histone deacetylase 1 (HDAC1), was also increased in bone marrow cells of 
SSAT mice compared to wild-type mice and the cells did show slight changes in their 
histone methylation profile. Additionally, the myeloproliferative phenotype of SSAT mice 
was attenuated when they were exposed to decitabine, a DNA methyltransferase drug that 
is in clinical use. These data indicate that the myeloproliferation found in SSAT 
overexpressing mice is related to epigenetic changes in the hematopoietic cells.  
The enhanced polyamine cycle and concomitantly the increased acetylpolyamine oxidase 
activity lead to the production of ROS which could potentially increase the level of 
oxidative stress in SSAT mice. As a matter of fact, recently our group reported mice over-
expressing SSAT under the control of a metallothionein promoter (MT-SSAT mice) had an 
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increased cellular protein carbonyl content which was interpreted as an indication of 
enhanced oxidative stress (Cerrada-Gimenez et al. 2011). Additionally, overall MT-SSAT 
mice have a very similar phenotype to the SSAT mice used in the present experiments, 
including similar changes in their blood cell count (unpublished data). Interestingly, ROS 
have been implicated in hematopoietic malignancies as there is evidence for the presence of 
chronic oxidative stress in chronic myeloid leukemia (CML) and acute myeloid leukemia 
(AML) (Ahmad et al. 2008; Sallmyr et al. 2008).  Furthermore, in normal hematopoiesis, 
ROS are indicated to have signaling functions being linked especially to differentiation of 
myeloid lineage cells, e.g. ROS are involved in promoting differentiation of Drosophila 
hematopoietic cells akin to the mammalian myeloid progenitors (Owusu-Ansah and 
Banerjee 2009). In addition, in murine myeloid progenitors, the ROS level has been shown 
to be higher than that of hematopoietic stem cells and increased levels of intracellular ROS 
in hematopoietic cells led to a myeloproliferative phenotype in mice which had a 
conditional deletion of all FoxO isoforms (Tothova et al. 2007). In addition to differentiation 
of myeloid cells, ROS have been shown to contribute to the lineage commitment of 
megakaryocytes (Eliades et al. 2012; Sardina et al. 2010). Thus, increased oxidative stress, if 
present in SSAT mice, could represent a possible mechanism to account the increased 
myeloproliferation seen in these mice. 
The bone marrow microenvironment is implicated to be associated with myeloid lineage 
commitment of hematopoietic cells. In mouse models it has been shown that the bone 
marrow microenvironment contributes to the development of myeloproliferation (Askmyr 
et al. 2011; Walkley et al. 2007). Moreover, humans with myeloid diseases suffer from 
related bone defects. However, the exact cell type within the microenvironment influencing 
the myeloproliferation is not known in either case. The key component supporting HSC, 
however, is known to be the osteoblastic cell (Calvi et al. 2003; Zhang et al. 2003). The first 
experiments highlighting the importance of osteoblasts in HSC maintenance was conducted 
with mice having a conditional inactivation of bone morphogenetic protein receptor type 
IA (BMPRIA) (Calvi et al. 2003). These mice show, similarly to the situation in SSAT mice, 
an increase in their LT-HSC numbers (II) which was evoked by an increase in the numbers 
of early osteoblastic cells. Furthermore, a subsequent study by Raaijmakers et al 
(Raaijmakers et al. 2010; Zhang et al. 2003) emphasized the importance of osteoprogenitors 
in sustaining hematopoiesis. Interestingly, although osteoblasts of SSAT mice had an 
impaired osteogenic potential, the serum concentration of a bone formation marker PINP 
was increased, thus, indicating that the number of osteoblastic cells was increased in vivo in 
SSAT mice. In support of this proposal, SSAT mice had also an increased number of 
trabeculae which are the main sites for osteoblastic cells. SSAT HSCs showed increase in 
proliferation rate compared to wild-type HSCs and decrease in expression of PU.1 which is 
not only a differentiation marker but also a regulator of HSC maintenance (Iwasaki et al. 
2005b). However, no changes were observed between wild-type and SSAT mice in other 
self-renewal markers, GFI, BMI, GATA-2 or HOXB4, or in the proportion of apoptotic 
HSCs. Thus, the expansion of the HSC pool in SSAT mice was not due to promotion of self-
renewal or to a block of apoptosis. All of these findings indicate that it is the osteoblastic 
cells, rather than some intrinsic mechanisms which are likely to be responsible for the 
increase in HSC number in SSAT mice. Furthermore, osteoblasts may take part also in the 
regulation of lineage commitment in these mice.  
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IV Bone remodeling and structure in SSAT mice 
SSAT overexpression elicited striking changes in the structure of bones in SSAT mice. 
Outwardly the most apparent skeletal change was the hunched back. The long bones of 
SSAT mice were larger in perimeter and the cortex became strikingly thin with age. The 
bones of old SSAT mice snapped more easily than those of wild-type or SSATKO mice 
when subjected to compression. The striking diminution of cortex explains the fragility to 
compression. However, SSAT bones tolerated bending slightly better than wild-type or 
SSATKO mice, which is understandable as the cortical bone of SSAT mice was larger in the 
perimeter. SSAT osteoblasts were indicated to have a defect in the mineralization steps of 
bone formation. However, there were no differences in the total bone mineral content of old 
wild-type, SSAT and SSATKO mice but since the bones of SSAT mice were of a different 
size than those of wild-type or SSATKO mice and the bone volume (BV) was increased in 
these mice, there may be differences in the relative mineral density between the genotypes. 
Thereby, since the bone mineral density of SSAT mice could not be confirmed, the bone 
phenotype of these mice could not be designated as osteopenic/osteoporotic.  
The osteoblastogenesis of SSAT mice was cell-autonomously impaired as the activity of 
alkaline phosphatase (ALP), an enzyme required for generation of inorganic phosphate for 
hydroxyapatite crystallization, was decreased in in vitro differentiated SSAT osteoblasts. 
Additionally, calcium nodules were nearly absent and there was reduced gene expression 
of late osteogenic markers. The osteoblasts of mice deficient for SSAT showed opposite 
features, thus, supporting the view that the level of SSAT activity affected 
osteoblastogenesis. Serum markers supported the in vitro results of impaired mineralization 
steps of bone formation in SSAT mice as there was a reduction in the concentration of 
osteocalcin, a protein which binds the hydroxyapatite mineral of bone matrix. However, 
even though the maturation of osteoblasts was impaired, the circulating PINP was slightly 
increased. PINP is a byproduct of collagen cleavage and thus a marker of bone formation 
rate. The increased activity of PINP, thereby, indicated the numbers of osteoblastic cells 
were increased in SSAT mice. SSAT osteoclasts displayed no notable changes in their 
number in cell culture, but the reduced serum tartrate-resistant acid phosphatase 
(TRAcP5b) concentration indicated that their number in vivo was decreased (Alatalo et al. 
2004). Despite the decreased number of osteoclasts, their activity, as measured by a marker 
of collagen degradation (CTX), remained comparable between wild-type and SSAT mice. 
This indicated that the relative activity of osteoclasts (activity per osteoclast) was increased 
in SSAT mice. The expression of the master transcriptional regulator of osteoclastogenesis, 
NFATc1, was increased in SSAT osteoclasts. However, this was not reflected in the 
expressions of either TRAcP or cathepsin K (CTSK). The lack of effect on osteoclastogenic 
markers may have been due to the early time-point used in the experiment. Taken together, 
the bone phenotype of SSAT mice resulted, for the most part, from an impaired function of 
osteoblasts. 
A recent study has shown that polyamines enhance osteoblastogenesis (Lee et al. 2013). 
However in SSAT mice, although the osteoblastic concentration of spermidine was 
reduced, the mechanism leading to defective osteoblastogenesis appeared to be related to 
the induction of SSAT enzyme activity. First of all, the treatment of SSAT osteoblasts with a 
spermidine analogue did not improve osteoblastogenesis in the SSAT mice. Secondly, 
SSATKO osteoblasts showed a significantly higher osteoblastogenic potential than that of 
SSAT mice, even though their polyamine levels did not dramatically differ from each other. 
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Finally, the osteoblastogenesis in the wild-type osteoblasts was decreased to the level of 
SSAT osteoblasts in response to addition of α-methylspermidine to the culture media and 
the common feature with the analogue-treated wild-type and SSAT osteoblasts was the 
high enzymatic activity of SSAT. In contrast to the situation in hematopoietic cells, the 
increased SSAT activity did not affect the acetylation status of histone protein 3 in the 
osteoblasts of SSAT overexpressing mice (data not shown). Thus, the effect of polyamine 
catabolism on osteoblastogenesis could be mediated through increased oxidative stress. The 
MT-SSAT mice, which have been reported to have increased oxidative stress, express also 
increased levels of p53 and age prematurely (Cerrada-Gimenez et al. 2011). Similarly to 
SSAT mice, MT-SSAT mice display skeletal changes such as kyphosis (unpublished data). 
Age-related changes in the bone phenotype, such as expansion of marrow space and 
thinning of cortex, are known to result from increased oxidative stress in mice (Almeida et 
al. 2007a; Levasseur et al. 2003). Aging mice suffer defects in osteoblastogenesis and, 
additionally, the number of osteoclasts declines with age (Almeida et al. 2007b). 
Additionally in humans, osteoblastogenic potential of mesenchymal stromal cells (MSCs) is 
reduced with age (D'Ippolito et al. 1999). Moreover, oxidative stress has been demonstrated 
to impair osteoblastogenesis also in rabbit MSCs and gamma-glutamyl transpeptidase 
(GGT) deficient mice (Bai et al. 2004; Levasseur et al. 2003). Therefore, premature aging and 
oxidative stress would seem to be plausible explanations for the changes seen in 
osteoblastogenesis and in bone phenotype of SSAT mice.  
 
  
39 
 
7 Summary and conclusions 
Not much is known about the role of polyamines, let alone about SSAT, in the immune 
response, hematopoiesis and bone formation. These present studies have shed some light 
on the role of enhanced polyamine catabolism in these processes. The results demonstrated 
that it was the presence of enhanced polyamine catabolism, rather than the polyamines 
themselves, which disturbed bone formation in SSAT overexpressing mice. Aberrant bone 
formation evoked changes in the bone marrow microenvironment which, together with 
intrinsic SSAT overexpression of hematopoietic cells, resulted in a myeloproliferative 
disease in these mice. The observation that SSAT activity was associated with the white 
blood cell count in human myeloid leukemias is further support for the view that SSAT 
activity is connected to myeloid cell development. 
I SSAT mice displayed no difference in their response to endotoxic shock with respect to 
survival or symptoms. However, at the molecular level, SSAT mice showed a slightly 
enhanced anti-inflammatory response. The basal levels of serum cytokines and acute-phase 
protein expressions of SSAT mice were comparable to those in their wild-type littermates 
which indicated SSAT mice did not suffer from a systemic chronic inflammation in the 
basal state.  
II The investigation of hematopoietic phenotype of SSAT mice revealed an enhanced 
blood leukocyte count dominated by mature neutrophils at the expense of lymphocytes. 
The blood platelet number was also increased whereas the red blood cell count decreased 
with age, causing anemia. In addition, the spleens of SSAT mice were larger than those of 
their wild-type counterparts and the bone marrow cellularity was increased revealing the 
presence of enhanced myelopoiesis and thrombocytopoiesis. The numbers of long-term 
hematopoietic stem cells and granulocyte-macrophage progenitors were increased in the 
bone marrows of SSAT mice whereas the number of megakaryocyte-erythrocyte 
progenitors was reduced. Altogether, the hematopoietic phenotype of SSAT mice fulfilled 
the criteria of mouse myeloproliferative disease. The myeloproliferative phenotype of SSAT 
mice resulted from both the intrinsic SSAT overexpression and from microenvironmental 
factors. The myeloproliferative phenotype of SSAT mice indicated that the enhanced SSAT 
activity was participating in myeloid differentiation. 
III Patients with chronic myeloid leukemia, acute myeloid leukemia and acute lymphoid 
leukemia showed increased levels of spermidine and spermine and enhanced SSAT activity 
in their peripheral blood mononuclear cells. The increased SSAT activity was associated 
with the increased number of white blood cells in myeloid leukemias but not in lymphoid 
leukemia. This supported the findings from SSAT mice that SSAT activity was associated 
with myeloproliferation. The myeloproliferation of these mice was considered to be 
connected to epigenetic factors as the SSAT mice showed a differential response to human 
leukemia drugs affecting epigenetics and the acetylation and methylation patterns of bone 
marrow cells differed from those found in their wild-type controls. 
IV The bones of SSAT mice broke more easily than those of wild-type mice when 
compressed. The long bones of SSAT mice were enlarged at the perimeter yet had a 
strikingly thinned cortical wall. The thickness of the trabeculae was also decreased in SSAT 
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mice but their number was increased. Osteoblastogenesis was cell-autonomously impaired 
in SSAT mice. Nevertheless, there appeared to be a greater number of premature 
osteoblasts. Altogether, the cellular and structural changes in the bones meant that there 
was a larger niche for hematopoietic cells. Thus, the bone phenotype studies supported the 
view that the myeloproliferation of SSAT mice was partly due to bone marrow 
microenvironmental factors. The study also indicated that SSAT activity impaired 
osteoblastogenesis through some mechanism other than depletion of polyamine levels. This 
mechanism could potentially be through excess production of ROS.  
These findings increase our understanding of the role of polyamine metabolism in 
hematopoiesis and bone remodeling. Together with earlier studies, these present findings 
emphasize the important role of SSAT in myeloid cell differentiation. In addition, these 
studies contribute to the body of research investigating the interplay between 
hematopoietic cells and bone microenvironment. Importantly, they also highlight the 
contribution of the catabolic part of the polyamine cycle in pathophysiological processes. In 
particular, highlighting the possibility that functions other than polyamine depletion may 
be responsible for the disturbed cellular homeostasis in bone forming cells and perhaps also 
in hematopoietic cells.  
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Polyamines are ubiquitious 
molecules essential for cell 
proliferation. However, the 
role of polyamine metabolism 
in the immune response, 
hematopoiesis, and bone 
remodeling is largely unknown 
and was thus addressed in this 
study. The study showed that 
enhanced activity of spermidine/
spermine N1-acetyltransferase 
(SSAT), a catabolic regulator of 
polyamines, was associated with 
disturbed hematopoiesis and bone 
remodeling in mice and myeloid 
leukemias in humans.
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